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1. SUMMARY 
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In recent decades, obesity has become a prominent health problem in many countries. It is 
closely linked to cardiovascular disease, type 2 diabetes mellitus and metabolic syndrome, 
resulting in increasing morbidity and mortality. Hence, it is necessary to develop effective 
prevention and treatment of obesity. 
In this study, we examined whether GMG-43AC, the new experimental drug of Giuliani Sp. 
A. (Milano, Italy), could inhibit the differentiation induced by a hormone mixture (IBMX, 
DEX and insulin) or troglitazone of 3T3-L1 preadipocytes, and further explored the possible 
mechanism of action. 3T3-L1 cells constitute one of the most popular in vitro models for the 
investigation of adipogenesis. To achieve the goals proposed in this research project it was 
necessary to set up: a) the differentiation protocol for 3T3-L1 cells; b) the colorimetric 
technique for detecting adipocytes droplets, and c) the quantification assay for accumulated 
triglycerides. In our experimental conditions droplets of triglycerides accumulated in 
differentiated 3T3-L1 cells were highly positive to the Oil Red O staining. 
As evidenced by Oil Red O staining, GMG-43AC dose-dependent inhibited triglycerides 
synthesize and accumulate at concentrations of 500, 1000 and 2000 µM.  
Studies in adipogenic cell lines have shown that the differentiation of preadipocytes into 
adipocytes is accompanied by changes in gene expression: e.g., a dramatic increase in the 
expression of the CCAAT/enhancer-binding proteins C/EBPβ and C/EBPδ followed by the 
expression C/EBPα and the nuclear hormone receptor peroxisome proliferator-activated 
receptor γ (PPARγ). 
At the molecular level, the expression of transcription factors, C/EBPβ, PPARγ and C/EBPα, 
was reduced by GMG-43AC during adipogenesis. After treatment for 10 days, the mRNA 
levels of adipocyte-specific genes, such as FABP-4 and leptin, were also down-regulated by 
GMG-43AC in a dose-dependent manner. Furthermore, the exposure to GMG-43AC during 
the initial 48 hours of adipocyte differentiation markedly reduced C/EBPβ levels in a dose-
dependent manner with the exception of the dose 300 µM.  
Moreover, we investigated the capability of GMG-43AC to revert the adipocyte 
differentiation process induced by hormone stimulants or troglitazone. We observed that 
GMG-43AC was able to revert the adipocyte phenotype in fully differentiated adipocytes. 
The reverting effect of GMG-43AC treatment can be observed from concentrations of 500 
µM or greater. Interestingly, the drug left in the culture medium for the period of 14 days 
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became more effective in the reversion of differentiation with respect to the treatment for 7 
days. The accurate molecular mechanisms that regulate loss of accumulated triglycerides in 
fully differentiated adipocytes are still unclear and will be investigated in the near future. 
Thus, GMG-43AC has the potential to be an innovative product for the prevention and 
treatment of obesity. 
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2. INTRODUCTION 
 9 
 
2.1. Introduction to obesity 
Obesity is one of the world's greatest public health challenges, contributing to morbidity and 
mortality through the increased risk for many chronic diseases, including type 2 diabetes, 
hypertension, dyslipidemia, coronary artery disease, stroke, osteoarthritis and certain forms of 
cancer (Youngson NA et al., 2012). Obesity is a multifactorial disorder and it is most 
commonly caused by a combination of excessive food energy intake, lack of physical activity, 
and genetic susceptibility, although a few cases are caused primarily by alterations, 
endocrine disorders, medication or psychiatric illness (Hossain P et al., 2007). 
Body weight regulation depends on the interaction between genetic, environmental and 
psychosocial factors. The prevalence of obesity is increasing worldwide at an alarming rate, 
which indicates that the primary cause of the excessive energy storage lies in environmental 
and behavioural changes rather than in genetic modiﬁcations. The factors that influence body 
weight regulation ultimately act by a chronic modification of the energy balance equation: 
Energy stored = energy intake - energy lost in feces and urine - energy expenditure 
Obesity is a problem of imbalance between energy intake and expenditure. Cellular events 
can cause obesity only if they affect energy balance (Fig.1). This means that changes in the 
expression of genes which control the differentiation and the development of adipocytes are 
not primarily responsible for the gain in body weight. A minor imbalance between energy 
intake and energy expenditure may lead to severe obesity: if energy intake exceeds energy 
expenditure by 5% every day, this results in a gain of 5 kg fat mass over one year, and to 
morbid obesity over several years (Jéquier E, 2002). 
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Fig. 1 The major causal linkages among genetics, environmental effects, physiology, behaviour, and 
energy balance (from Speakman JM, 2004). 
 
The increase in the prevalence of obesity has been observed worldwide, and will most likely 
continue to be an important risk factor for the health of all populations, in particular of those 
in developing countries (Day FR et al., 2011). Over the past 20 years, the rate of obesity has 
tripled in developing countries. Obesity has become recognized as one of the major health 
problems threatening the world today, along with malnourishment and infectious diseases. 
The International Obesity Task Force and the World Health Organization (WHO) report over 
1.1 billion adults worldwide are overweight, 312 million of whom are obese. In addition, over 
155 million children are overweight or obese worldwide; 42 million of these children are 
under the age of 5. The areas of the world at greatest risk due to due to increasing prevalence 
are the Middle East, Pacific Islands, Southeast Asia, and China. Obesity is highly prevalent in 
the middle-income countries of Eastern Europe, Latin America, and Asia, where obesity is the 
fifth most common cause of disease, ranking just below malnourishment (Hossain P et al., 
2007; Haidar YM et al., 2011). 
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 2.1.1. Effects of obesity 
Obesity's health risks include a long list of debilitating but not life-threatening diseases like 
respiratory difficulties, osteoarthritis, skin problems, infertility, etc. Increased body fat leads 
to adverse metabolic effects on blood pressure, insulin resistance, and cholesterol levels. The 
major obesity-associated conditions stem from these metabolic effects: cardiovascular 
disease, type 2 diabetes, cancers (particularly colorectal, breast, prostate, endometrial, kidney, 
and gallbladder), and gallbladder disease (Hossain P et al., 2007; Haidar YM et al., 2011). 
The risk of cardiovascular disease is considerably greater among obese people, and this group 
has an incidence of hypertension that is greater in comparison to people of normal 
bodyweight (Hossain P et al., 2007). 
The increase in the prevalence of type 2 diabetes is closely linked to the upsurge in obesity. 
About 90% of type 2 diabetes cases can be attributed to excess weight. Furthermore, obesity-
related metabolic syndrome causes impaired glucose tolerance in 197 million people 
worldwide. This number is expected to increase to 420 million by 2025, with the most 
prominent increase in developing countries (Hossain P et al., 2007; Haidar YM et al., 2011). 
Obesity, diabetes, and hypertension also affect the kidneys. Diabetic nephropathy develops in 
about one third of patients with diabetes, and its incidence is sharply increasing in the 
developing world. The WHO Multinational Study of Vascular Disease in Diabetes showed 
that proteinuria was associated with an increased risk of death from chronic kidney disease or 
cardiovascular disease, as well as of death from any cause (Hossain P et al., 2007). 
 
2.1.2. Childhood obesity 
Childhood obesity is a global problem, but the prevalence is higher in developed countries, 
particularly the United States. Changing diet and decreasing physical activity are believed to 
be the two most important factors in causing the recent increase in the rates. Worldwide, the 
childhood obesity prevalence in 2010 was 6.7%. Interestingly, in both developed and 
developing countries, the prevalence of overweight girls is greater than overweight boys, 
particularly among adolescents: 70% of obese adolescents become obese adults. This has led 
many observers to view childhood obesity as the root of the obesity problem, and also its most 
potentially tractable element (Haidar YM et al., 2011). 
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2.1.3. Etiology 
Rising incomes, increasing urban populations, diets high in fats and simple sugars, and a shift 
toward less physically demanding jobs are some of the societal changes resulting in increased 
obesity. Less physical activity is promoted by automated transport, labor-saving technology in 
the home and workplace, television, and computer games. These changes in the social 
environment promote excessive food intake and decreased physical activity, leading to 
obesity. Studies in humans have shown that a high-fat diet (>35% of calories from fat) leads 
to increased energy intake, efficiency of body fat gain, and obesity (Haidar YM et al., 2011). 
 
2.1.4. Genetics 
Numerous studies have confirmed the contribution of genetics in the obesity epidemic. 
Ten percent of morbidly obese children come from consanguineous families, suggesting that 
other forms of genetic links are present (Friedman JM, 2003; Haidar YM et al., 2011). There 
are clear genetic elements in obesity. Genetic polymorphisms, causing decreased or 
nonfunctional levels of leptin or malfunctioning mutations in the leptin receptor, result in an 
abnormally high appetite and obesity beginning in childhood (Haidar YM et al., 2011). 
Obesity is a problem of imbalance between energy intake and expenditure. The expansion of 
the prevalence of obesity reflects changes that have occurred in our behaviour (activity and 
food intake) that are dependent on the changing environment rather than the effects of 
population genetics. Moreover, the susceptibility of individuals to obesity is differential. 
Whatever environment or time period we choose, we find a mix of obese and lean people. 
These differences may reside in the microstructure of the environment experienced by each 
individual or may depend on genetic differences. An important point to recognize is that 
genetics and environmental factors exert their effects on energy balance and obesity via 
effects on our behaviour and physiology (Fig. 1). There is no direct link between our genes 
and our body weight or fatness. This is frequently misunderstood as is evidenced by 
discussions about whether obesity is caused by our genes or our behaviour. Behaviour and 
genes are different levels of the same causal framework. Consequently, although we might 
say that obesity has a large genetic component to it, this doesn't mean that the obese have 
somehow miraculously deposited enormous quantities of body fat without eating too much 
food, or expending too little energy, or doing both (Speakman JM, 2004). 
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2.1.5. Energy homeostasis 
Energy homeostasis is controlled by neurons in the hypothalamus that regulate both appetite 
and metabolism. Endocrine signals such as glucose, insulin, free fatty acids, and leptin send 
messages about the body's energy state to the hypothalamus, thus controlling the firing of 
these neurons (Haidar YM et al., 2011). Leptin is a 167-amino acid peptide hormone encoded 
by the obesity (ob) gene and secreted by white adipocytes. Leptin is the satiety hormone, 
providing negative feedback to the hypothalamus to control appetite and energy expenditure 
(Feng H et al., 2012). The blood concentration of leptin is increased in obese individuals. 
Circulating leptin can cross the blood–brain barrier and bind to receptors (LEPR) in the brain, 
where it acts to decrease food intake and promote energy expenditure. With weight loss, 
circulating leptin decreases, leading to increased appetite and decreased energy expenditure. 
Variation among individuals may explain why some people seem protected against becoming 
overweight despite living in the same environment and consuming the same food as the obese. 
The leptin system also helps explain why it is more difficult to lose weight than to gain. 
Genetic deficiency of leptin or its receptors results in abnormally high appetite followed by 
the extent of fat stores. The consequent extreme hyperphagia and reduced energy expenditure 
produce massive obesity (Haidar YM et al., 2011; Feng H et al., 2012). 
 
2.2. GMG-43AC features 
GMG-43AC is a new experimental drug from Giuliani Sp.A (Milano, Italy). GMG-43AC is a 
white powder with molecular weight at 237.22 gr/l. It is soluble in DMSO (dimethyl 
sulfoxide) (up to 0.1-1 gr/ml) and also in water (up to 1-10 gr/l).  
Calculated physic-chemical proprieties: 
Conditions: 
• Temperature 250C 
•  Pressure 760 mmHg 
• Vapour pressure -12.56 log(atm) 
• Boiling point 350.70C 
• Water diffusion 6.06x10-6cm2/sec 
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• Density 1.19 g/cm3 
• Refractive index 1.53 
• Electron affinity -0.24 eV 
• Heat of vaporization 34,97 Kcal/mol 
• Air diffusion 0.044 cm2/sec 
• Volume 199.3 cm3/mol 
• Polarizability 24.44 Å3 
• logP (octanol/water) 1,79 
 
Table 1. Physic-chemical proprieties of GMG-43AC. 
 
2.3. Introduction to adipogenesis  
The adipocytes play a critical role in energy balance. Adipogenesis is a hyperplasia process of 
adipose cells. It begins with a common multipotent precursor cell, that progressively goes 
through four sequential phases (Fig. 2): preconfluent proliferation; growth arrest; clonal 
expansion and terminal differentiation (Gregoire FM  et al., 1998; Hansen JB et al., 1999; 
Prusty B et al, 2002; Fève B, 2005). 
A confluence, induction of differentiation by appropriate treatment leads to cell shape 
changes. The preadipocyte converts to a spherical shape, accumulates lipid droplets, and 
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progressively acquires the morphological and biochemical characteristics of a mature 
adipocyte. During adipocyte differentiation cell morphology, cytoskeletal components and 
the level and type of extracellular matrix components (ECM) change (Gregoire FM et al., 
1998; Fève B, 2005). 
 
 
Fig. 2 Summary of in vitro adipocyte differentiation (from Cowherd RM et al., 1999). 
 
Adipogenesis starts when cells stop growing as a consequence of contact inhibition. In 
the clonal expansion phase cells can re-enter in the cell cycle and divide once or twice. This 
phase occurs after confluent cells are treated with differentiation-inducing agents (see: part 
1.3.1.). The last phase of adipogenesis is the terminal differentiation. In this phase 
the preadipocyte takes on the characteristics of the mature adipocyte - it acquires 
the machinery that is necessary for lipid transport and synthesis, insulin sensitivity and 
the secretion of adipocyte-specific proteins. During the terminal phase of differentiation, 
activation of the transcriptional cascade leads to increased activity and mRNA levels for 
enzymes involved in triacylglycerol synthesis and degradation. Glucose transporters, insulin 
receptor numbers, and insulin sensitivity also increase. Synthesis of adipocyte-secreted 
products including leptin, adipsin, resistin, etc.  
 
Several cellular models are available to study adipogenesis that involve almost all stages of 
development, such as embryonic stem cells and mouse embryo fibroblasts. The cellular and 
molecular mechanism of adipocyte differentiation has been studied by using preadipocyte 
culture systems. Various preadipocyte cell lines and primary cultures of adipose-derived 
stromal vascular precursor cells have been used. The most frequently employed murine cell 
lines are 3T3-L1 and 3T3-F442A. These were clonally isolated from Swiss 3T3 cells derived 
from 17- to 19-day mouse embryos. The most popular human model is represented by human 
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primary white adipocyte cells isolated from fat biopsies. In vitro-differentiated adipocytes 
have many characteristics of adipose cells in vivo. The 3T3-L1 mouse cells differentiate 
spontaneously when exposed to a hormonal cocktail composed of dexamethasone (DEX), 3-
isobutyl-1-methylxanthine (IBMX), and high concentration of insulin (Gregoire FM et al., 
1998; Prusty B et al., 2002; Fève B, 2005). 
 
2.3.1. The role of dexamethasone, 3-isobutyl-1-methylxanthine, and insulin in 
3T3-L1 adipocyte differentiation 
3T3-L1 cells (Fig. 3, top panel), can be 
stimulated to undergo differentiation to 
adipocytes by the addition of IBMX, 
dexamethasone and insulin. Dexamethasone 
(DEX) is a synthetic glucocorticoid. It has 
been demonstrated in 3T3-L1 cells that 
glucocorticoids induce expression of  C/EBPδ. 
This increase may contribute to the formation 
of C/EBPβ-C/EBPδ heterodimer, which in 
turn may leads to PPARγ and C/EBPα 
expression. Moreover, DEX inhibits the 
transcription of protein Pref-1 (preadipocyte 
factor-1) which is the marker of preadipocytes 
and also the inhibitor of adipogenesis (Sul HS, 
2009). 3-isobutyl-1-methylxanthine (IBMX) 
is a xanthine derivative. IBMX is a 
phosphodiesterase inhibitor which raises 
intracellular cAMP level. This step is crucial 
for the induction of adipocyte differentiation. 
High level of cAMP actives cAMP response 
element-binding (CREB) and in consequence 
induces the expression of C/EBPβ. It was 
shown that IBMX accelerates the adipogenesis 
and slows the proliferation (Gregoire FM 
et al., 1998; Cowherd RM et al., 1999). 
 
Fig. 3 Stimulation of adipogenesis process in 
vitro. Preadipocytes, such as 3T3-L1 cells (top 
panel), can be stimulated to undergo 
differentiation to adipocytes by addition of 
IBMX, dexamethasone and insulin. IBMX 
increases intracellular cAMP, dexamethasone 
binds to the glucocorticoid receptor and insulin 
binds to the insulin receptor. These three 
pathways culminate in activation of the PPARγ 
and C/EBP family genes. Adipocytes (lower 
panel) contain PPARγ and C/EBPα, which 
activate adipocyte-specific genes encoding 
secreted factors, insulin receptor, and proteins 
involved in the synthesis and binding of fatty 
acids that compose Oil Red O-stainable lipid 
droplets. 
 
 17 
 
Insulin has a prominent and complex role in the development of adipose cells, serving as 
a growth or differentiation factor depending on the specific cell type. Insulin has marked 
effects on adipogenesis. In the early stages of adipogenesis, insulin functions predominantly 
through insulin growth factor-1 (IGF-1) receptor signalling. The IGF-1 and insulin receptors 
are tyrosine kinases that can activate the Ras-MAPK pathway. Insulin is a weak activator of 
ERK2 but is unable to activate ERK1, nevertheless, it is able to potentiate the phosphorylation 
of both of these kinase in the presence of IBMX and DEX (Prusty D et al., 2002). 
Preadipocytes express many more receptors for IGF-1 than for insulin, although this ratio 
shifts during differentiation proceeds (Hu E et al., 1996). From the metabolic point of view 
insulin stimulates the GLUT-4 translocation and glucose entries in adipose cells. Downstream 
components of the insulin/IGF1 signalling cascade are also crucially important for 
adipogenesis (Fig. 4). The loss of individual insulin-receptor substrate (IRS) proteins inhibits 
adipogenesis, with an order of importance of IRS1>IRS3>IRS2>IRS4. IRSs, in the early 
phase of differentiation, directly regulate the expression of PPARγ and  C/EBPα  by the 
activation of CREB. Moving down the insulin signalling cascade, inhibition of 
phosphatidylinositol-3 kinase (PI3K) as well as loss of AKT1/protein kinase B (PKB) or 
AKT2/PKB blocks adipogenesis (Garofalo RS et al., 2003; Xu J et al., 2004). Other 
downstream effectors of insulin action, such as mammalian target of rapamycin (mTOR), 
have also been shown to be involved in adipogenesis (Kim JE et al., 2004). Moreover, insulin 
inhibits the hormone sensitive lipase activity reducing the release of free fatty acids. Insulin 
acutely inhibits lipolysis via inhibition of the above cAMP-dependent pathway by PKB-
dependent phosphorylation and activation of phosphodiesterase, which in turn lowers cAMP 
levels (Kershaw EE et al., 2006). At the same time, insulin inhibits GATA2 and GATA3 
factors that act as differentiation inhibitors (Rosen ED et al., 2006). 
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Fig. 4 Regulation of adipogenesis by extracellular factors. Signals from activators and repressors of 
adipogenesis are integrated in the nucleus by transcription factors that directly or indirectly regulate expression 
of peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT-enhancer-binding protein α (C/EBPα). 
In the scheme it is emphasized the role of insulin/IGF-1 (from Rosen ED et al., 2006). 
 
2.3.2. Key molecular factors in adipose differentiation process 
The adipogenesis is accompanied by a dramatic increase in expression of adipocyte genes 
(Fig.5). 
 
 
Fig. 5 Representative scheme of adipocytes differentiation and molecular events that take place 
(from Fève B et al., 2005). 
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At least two families of transcription factors, C/EBP (CCAAT/enhancer binding protein) and 
PPAR (peroxisome proliferator-activated receptors), are induced early during adipocyte 
differentiation (Fig. 6). PPARγ is a member of a nuclear hormone receptor superfamily. 
There are 2 isoforms of PPARγ: γ1 and γ2. The isoform γ1 is found in the many different 
tissues such as heart, skeletal muscle, colon, small and large intestines, kidney, pancreas and 
spleen, while expression of PPARγ2 is predominantly localized to adipocytes (Cowherd RM 
et al., 1999; Berger J et al., 2002). PPARγ is crucial for adipogenesis and also is required for 
maintenance of the differentiated state. PPARγ is adipose specific and is expressed at low but 
detectable levels in preadipocytes (Gregoire F et al., 1998). Its expression rapidly increases 
after hormonal induction of differentiation. It is easily detectable during the second day of 
3T3-L1 adipocyte differentiation (Fig. 6) Maximal levels of expression are noted in mature 
adipocytes. PPARγ regulates the expression of key genes involved in lipid and glucose 
metabolism or adipocyte differentiation, such as FABP-4, LPL, GLUT4.  The genes regulated 
by PPARγ contain PPAR response elements (PPRE) (Rosen ED et al., 2006; Gregoire F et al., 
1998; Rangwala SM et al., 2000). The function of PPARγ is regulated by phosphorylation. 
In particular, PPARγ2 is phosphorylated at serine 112 by MAP kinase. The phosphorylated 
form has a lower affinity for ligand than the non-phosphorylated form. This phenomenon has 
negative effect on differentiation process and on the transcription of the genes regulated by 
PPARγ (see part 2.3.3.)  (Rangwala SM et al., 2000). 
 
 
Fig. 6 Timing of molecular factors expression during adipogenesis (from Rangwala SM et al., 2000). 
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Another molecular factor implicated in adipogenesis is C/EBP that is able to bind to 
the CCAAT sequence localized in the promoter region of many genes. There are three main 
isoforms of C/EBP protein present in adipocytes: α, β e δ.  Each isoform has a distinct 
temporal and spatial expression pattern during adipocyte differentiation (Fig. 6 and 7). During 
the initial phases of adipogenesis, C/EBPβ and C/EBPδ are induced in response to adipogenic 
hormones such as IBMX and DEX, respectively. C/EBPβ e C/EBPδ form a heterodimer that 
regulates the expression of PPARγ and C/EBPα (Fig. 7). The expression of PPARγ and 
C/EBPα  take place at the end of the clonal expansion when the terminal differentiation phase 
begins with the accumulation of triacylglycerol droplets in the cytoplasmic compartment and 
synthesis of specific cellular factors named adipokines such as leptin, adiponectin, omentin, 
resistin, angiotensinogen. C/EBPα is necessary for the acquisition of insulin sensivity. 
C/EBPα induces expression of PPARγ or vice versa (positive feedback) (Cowherd RM et al., 
1998; Gregoire F et al., 1998, Rosen ED et al., 2006).  
 
Fig. 7  Schematic interaction between pro-adipogenic and anti-adipogenic factors 
(from Rosen ED et al., 2006). 
 
In addition to transcription factors, other signalling molecules such as Pref-1 (preadipocyte 
factor-1) regulate adipocyte differentiation (Sul HS et al., 2000). Pref-1 is an inhibitor of 
adipocyte differentiation and is synthesized as a plasma membrane protein containing six 
EGF repeats in the extracellular domain. Pref-1 is highly expressed in 3T3-L1 preadipocytes, 
but is not detectable in mature fat cells. DEX, a differentiation agent, inhibits Pref-1 
transcription and thereby promotes adipogenesis. Downregulation of Pref-1 is required for 
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adipose conversion, and constitutive expression of Pref-1 inhibits adipogenesis. Conversely, 
decreasing Pref-1 levels by antisense Pref-1 transfection greatly enhances adipogenesis 
(Sul HS et al., 2000).   
The most popular markers used to characterize adipogenesis are FABP-4 and leptin. FABP-4 
is a carrier protein for fatty acids. This protein is also a marker for mature adipocytes 
(Wang M et al., 2009). Leptin is one of the most important adipose derived hormones 
(adipokine) and is primarily made and secreted by mature adipocytes (Gregoire F et al., 
1998). Expression of lipoprotein lipase (LPL) mRNA is an early sign of adipocyte 
differentiation. LPL is secreted by mature adipocytes and plays a role in controlling lipid 
accumulation (Gregoire F et al., 1998). 
 
2.3.3. Role of MAP kinases in adipogenesis regulation 
The ERK, p38 and JNK mitogen activated protein kinases (MAPKs) are intracellular 
signalling pathways that play a pivotal role in many essential cellular processes such as 
proliferation and differentiation. MAPKs are activated by a large variety of stimuli and one of 
their major functions is to connect cell surface receptors to transcription factors in the nucleus, 
which consequently lead to gene regulation and long-term cellular responses. All modules 
comprise two additional protein kinases activated in series and lead to activation of a specific 
MAP kinase: a MAP kinase kinase (MAPKK), represented by MEK or MKK proteins, which 
phosphorylates a specific MAPK, and a MAP kinase kinase kinase (MAPKKK), represented 
by Raf and MEKK proteins, which phosphorylates a specific MAPKK (Fig. 8) (Bost F et al, 
2005).  
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Fig. 8  MAPKs signal transduction pathways (from Bost F et al., 2005). 
 
MAP kinases ERK1 and ERK2 are activated by phosphorylation on threonine and tyrosine 
residues by the dual specificity kinase MEK1. MEK1 induces translocation of ERK1 and 
ERK2 into the nucleus where they activate or repress a variety of transcription factor involved 
in growth and differentiation (Prusty D et al., 2002). ERKs are required for differentiation of 
3T3-L1 fibroblasts to adipocytes, thereafter, this signal transduction pathway needs to be 
shut-off to proceed with adipocyte maturation. During the terminal differentiation, ERKs 
phophorylate PPARγ, decrease its transcriptional activity and inhibit adipocyte differentiation. 
The function of ERK in adipogenesis has to be time-regulated: during early phases of 
induction, ERK has to be turned on for a proliferative step, while later on, it has to be shut-off 
to avoid PPARγ phospshorylation. This hypothesis is in agreement with the fact that the 
adipocyte differentiation process of 3T3-L1 requires, at the beginning, a precise proliferative 
step, called mitotic clonal expansion (MCE), which takes place post-confluency. The MCE 
phase is initiated by adipogenic stimuli, such as insulin, which are known to activate the ERK 
pathway (Bost F et al., 2005). It was shown that insulin together with IBMX (MIX treatment) 
are principal regulators of MEK activity and promote adipose differentiation. On the contrary, 
the blockade of ERKs activity in 3T3-L1 cells by using specific inhibitors of MEK/ERK 
pathway (UO126 or PD98059) causes the inhibition of differentiation process (Prusty D et al., 
2002). Furthermore, PPARγ expression is not detected during MCE, and progressively 
increases during terminal differentiation, when ERK activity is returned to a low level. It has 
also been shown that ERK activity is necessary for the expression of the crucial adipogenic 
regulators like C/EBPα, β and δ and PPARγ. ERK phosphorylation of C/EBPβ activates its 
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transcriptional activity (Bost F et al., 2005). Moreover, it has been shown that in the late 
phase of the differentiation process MEK/ERK pathway regulates the activation state of 
PPARγ causing its phosphorylation. This post-translational modification of the protein causes 
its degradation via ubiquitin/proteasome system (Burns KA et al., 2007).  Other authors have 
shown that upon cellular stimulation MEK/ERK complex in the active state can translocate 
into the nucleus causing the phosphorylation of PPARγ and its export into the cytoplasm, 
where it is ubiquitinated and degradated (Fig. 9) (Burgermeister E et al., 2007). 
 
Fig. 9 Mechanism of PPARγ down-regulation by MEKs/ERKs (from Bost F et al., 2005). 
 
2.4. Regulation of lipolysis in 3T3-L1 adipocytes 
Lipolysis plays a central role in the regulation of energy balance. Lipolysis is the process in 
which triglycerides (TG) are hydrolyzed into glycerol and free fatty acids (FFA). This process 
releases FFA into bloodstream where they may be either re-esterified by the adipocyte or 
travel to other tissues and exert other effects throughout the body. FFA are an essential source 
of energy for many tissues. The control of lipolysis is complex and involves multiple players 
such as lipolytic (β-adrenergic agonists, ACTH, etc.) and anti-lipolytic (insulin, 
adenosine, etc.) hormones, their cognate receptors and signalling pathways, lipid droplet-
associated proteins, such as perilipins, and hormone-sensitive lipase (HSL) which is the rate-
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limiting enzyme responsible for mediating the hydrolysis of TG (Greenberg AS et al, 2001). 
The activity of HSL is well known to be regulated by reversible phosphorylation. Lipolytic 
stimuli increase lipolysis by activating adenylyl-cyclase and raising intracellular 
concentrations of cyclic AMP (cAMP), with resultant activation of cAMP-dependent protein 
kinase (PKA), which phosphorylates both perilipins and HSL. The phosphorylation of HSL is 
associated with an increase in hydrolytic activity of the enzyme and the translocation of HSL 
from the cytosol to the lipid droplet. In murine adipocytes, PKA phosphorylates HSL at 
several serine residues (563, 659, 660). In addition, HSL may be also phosphorylated by other 
kinases such as ERK1/2, which has been shown to activate HSL by phosphorylation on Ser600 
(Greenberg AS et al, 2001; Fernández-Galilea M et al., 2012). Insulin acutely inhibits 
lipolysis, at least in part, via inhibition of the above cAMP-dependent pathway by PKB-
dependent phosphorylation and activation of phosphodiesterase 3B, which in turn lowers 
cAMP levels (Fig. 10) (Kershaw EE et al., 2006). 
 
 
Fig. 10 Overview of adipocyte lipolysis (from Lipolysis Assay Kit for 3T3-L1 Cells: Glycerol 
Detection; ZENBIO).
  
3. AIM  
AIM 
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The principal goal of this project was to evaluate the effect of GMG-43AC, the new 
experimental drug from Giuliani Sp.A (Milan, Italy), on adipocyte differentiation by 
using various differentiation schedules: 
• differentiation induced by 3-isobutyl-1-methylxanthine (IBMX), dexamethasone 
(DEX) and insulin, 
• differentiation induced by troglitazone and insulin. 
The initial aim of this study was to set up the protocol of differentiation of 3T3-L1 cells 
and optimize protocols for the analysis of this phenomenon. Afterwards, the active 
concentrations of GMG-43AC were identified and the toxicity of the drug was assessed.  
In particular, the specific objectives related to the study of the effects of GMG-43AC 
were to evaluate effects of this drug on adipogenesis through cell count and 
the measurement of triglycerides after staining with Oil Red O. The mechanism of the 
action of GMG-43AC was studied with molecular analysis conducted by: 
• Western Blot - for the evaluation of protein factors involved in adipogenesis, 
• Immunofluorescence – to verify the presence and localization of protein 
fundamental for adipogenesis, 
• Real Time RT-PCR – to verify the gene expression crucial for adipocyte 
differentiation process. 
The achievement of the objectives listed above will make possible to evaluate the 
potential effects of GMG-43AC on obesity by determining the effects of this drug on 
preadipocyte differentiation into adipocytes in 3T3-L1 cells. 
 
 
  
4. MATERIALS AND 
METHODS 
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4.1. Materials and solutions 
4.1.1. Materials 
Insulin was purchased from SIGMA and dissolved in HCl 0.005N at the concentration 
of 10 mg/ml. Dexamethasone (DEX) was purchased from SIGMA and dissolved in 
DMSO at the concentration of 1 mM. 3-isobutil-1-metylxantine (IBMX) was purchased 
from SIGMA and dissolved in DMSO at the concentration of 0.5 M. PD98059 was 
purchased from SIGMA and dissolved in DMSO at the concentration of 6 mM. 
Troglitazone was purchased from SIGMA and dissolved in DMSO at the concentration 
of 10 μM. L-Thyroxine was purchased from SIGMA and dissolved in distilled water. 
Eutirox® was obtained from Bracco (Germany) and dissolved in distilled water. 
Caffeine was obtained from Giuliani Sp.A (Milano, Italy) and dissolved in distilled 
water at the concentration of 50 mM. GMG-43AC (levorotation isomer), RACEME and 
caffeine were obtained from Giuliani Sp.A (Milano, Italy) and were dissolved in DMSO 
at the concentration of 50 mM.  
The final concentration of DMSO added to the growth medium was less than 0.001%. 
 
4.1.2. Solutions 
Electrode buffer 1X 
192 mM Glycin (BDH; Manchester-UK) 
0.1% SDS (SIGMA) 
25 mM Tris (SIGMA) 
 
Transfer buffer 1X 
19 mM Glycin (BDH) 
2.5 mM Tris Base (BIO-RAD) 
2% Methanol (BDH) 
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Sample buffer 4X 
0.25 M Tris-HCl (BDH) pH 6.8 
36% Glycerol (SIGMA) 
8% SDS (SIGMA) 
0.2% Bromophenol blue (BIO-RAD) 
20% ß-mercaptoetanol (SIGMA). 
 
Ponceaus red 
0.2% (w/v) Ponceau’s (SIGMA) 
3% (w/v) TCA (SIGMA) 
3% sulfosalicylic acid (SIGMA) 
 
TBS 
20 mM Tris (SIGMA) 
500 mM NaCl (SIGMA) 
 
T-TBS 0.05%  
20 mM Tris (SIGMA) 
500 mM NaCl (SIGMA) 
0.05% Tween20 (SIGMA) 
 
Blocking buffer 
5% not fat milk powder (SIGMA) in T-TBS 0.05%. 
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PBS 0.01 M 
137 mM NaCl (SIGMA) 
2.7 mM KCl (BDH) 
1.47 mM KH2PO4 (BDH) 
8.1 mM Na2HPO4 (BDH) 
in dH2O. 
 
3T3-L1 maintenance medium  
87% DMEM 1 g/l D-glucose (Euro Clone) 
10% FBS (Euro Clone) 
1% Penicillin G potassic salt (100 U/ml) (Euro Clone) 
1% Streptomycin Sul fate (100 µg/ml) (Euro Clone) 
1% Glutamine (Euro Clone) 
 
3T3-L1 induction medium 1 
87% DMEM 4,5 g/l D-glucose (Euro Clone) 
10% FBS (Euro Clone) 
0,5 mM IBMX (SIGMA) 
1 µM DEX (SIGMA) 
10 µg/ml insulin (SIGMA) 
1% Penicillin G potassic salt (100 U/ml) (Euro Clone) 
1% Streptomycin Sulfate (100 µg/ml) (Euro Clone) 
1% Glutamine (Euro Clone) 
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3T3-L1 induction medium 2 
87% DMEM 4,5 g/l D-glucose (Euro Clone) 
10% FBS (Euro Clone) 
10 µg/ml insulin (SIGMA) 
1% Penicillin G potassic salt (100 U/ml) (Euro Clone) 
1% Streptomycin Sul fate (100 µg/ml) (Euro Clone) 
1% Glutamine (Euro Clone) 
 
3T3-L1 maintenance differentiation medium  
87% DMEM 4,5 g/l D-glucose (Euro Clone) 
10% FBS (Euro Clone) 
1% Penicillin G potassic salt (100 U/ml) (Euro Clone) 
1% Streptomycin Sul fate (100 µg/ml) (Euro Clone) 
1% Glutamine (Euro Clone) 
 
RIPA buffer 
40mM TRIS-HCl pH=7,5 (SIGMA) 
150mM NaCl (SIGMA) 
1% Triton X-100;  
0,1% SDS (SIGMA);  
0,5% sodium deoxycholate (SIGMA);  
0,1mM EDTA with protease inhibitor cocktail. 
in dH2O 
plus protease inhibitors: 
50 mM NaF (SIGMA) 
1 mM NaVO3 (SIGMA) 
4 mM PMSF (SIGMA) 
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1 M Benzamidine (SIGMA) 
1 M NaN3 (SIGMA) 
10 µg/ml Aprotinin (SIGMA) 
10 µg/ml Leupeptin (SIGMA) 
 
Oil Red O stock 
0.5g Oil Red O (SIGMA) 
in 100% isopropanol  
 
4.2. Methods 
4.2.1. Cell cultures and induction of differentiation in 3T3-L1 cells 
Mouse embryo fibroblast 3T3-L1 cells were obtained from the American Type Culture 
Collection (ATCC-CL-173). The cell line was originally derived from Swiss mouse 
embryos at 17 to 19 days of age (Kehinde and Green, 1975). 3T3-L1 preadipocytes 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Euro Clone) 
containing 1g/l D-glucose, 10% heat-inactivated fetal bovine serum (FBS) 
supplemented with antibiotics at 370C in a humidified atmosphere containing 5% CO2. 
The experimental conditions for achieving differentiation towards adipocyte and fat 
accumulation had been well described previously in Han KL et al., 2006; Kawaji A et 
al., 2010. Briefly, 2-3 days post-confluence (defined as day 0) cells were exposed to the 
adipocyte differentiating medium (DMEM) containing 4,5 g/l D-glucose, insulin (10 
µg/ml SIGMA),  dexamethasone (DEX; 1 µM SIGMA), and 3-isobutil-1-metylxantine 
(IBMX; 0.5 mM SIGMA) for 48 hours. Then, the differentiating medium was 
substituted with DMEM containing  insulin (10 µg/ml) for further 48 hours (defined as 
day 2). The last period of differentiation was conducted keeping the cells in regular 
growth medium (DMEM 4,5 g/l D-glucose with 10% fetal bovine serum). In our 
experiments the differentiation process latest 8-10 days (see scheme below). 
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4.2.2. Evaluation of the effects of GMG-43AC on in-vitro induction of 
adipogenesis  
GMG-43AC was diluted in DMSO and different quantities were added to the culture 
medium of 3T3-L1 cells to reach a final concentration ranging from 0.1 µM  to 2000 
µM. Cells were incubated with the drug in according to 4 different protocols as 
described below:  
1. GMG-43AC was added to the medium at day 0 of the differentiation process and 
maintained thereafter for the following 10 days  (scheme 1). 
2. GMG-43AC was added to the medium at day 0 and maintained for 48 hours 
during the early differentiation process (scheme 2) 
3. GMG-43AC was added to the medium at day 2 and maintained for 48 hours 
during the differentiation process (scheme 3) 
4. GMG-43AC was added to the medium at  day 2 and maintained until the end of 
the differentiation process (day 10; scheme 4) 
MATERIALS AND METHODS 
34 
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4.2.3. Reversion of adipogenesis process by GMG-43AC 
3T3-L1 were differentiated for 8 days as described before. The ability of GMG-43AC to 
revert the adipocyte differentiation process was evaluated at 2 different time points as 
presented on the schemes 5 and 6. GMG-43AC was added to the culture medium and 
maintained for the following 7 (scheme 5) or 14 days (scheme 6). The dosages of 
GMG-43AC tested in these experiments were 300 µM, 500 µM, 1000 µM and 
2000 µM.  
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4.2.4. Evaluation of the actions of GMG-43AC in adipogenesis induced 
by troglitazone (10 µM) 
Troglitazone, a potent inducer of adipocyte differentiation, was added at day 0 to the 
growth medium containing insulin (10 µg/ml) at the final concentration of 10 µM as 
described by Su TZ et al., 1998; Han KL et al., 2006; Kim KJ et al., 2010, and 
maintained until the end of the differentiation process (day 10; see scheme below). 
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4.2.5. Evaluation of the actions of GMG-43AC in recovery of 
adipogenesis induced by troglitazone (5 µM) 
3T3-L1 were differentiated in presence of troglitazone (5 µM) for 9 days as described 
before (see scheme 7). The ability of GMG-43AC to revert the adipocyte differentiation 
process was evaluated by adding the drug at day 9 to the culture medium and 
maintained for the following 7 or 14 days. The dosages of GMG-43AC tested in these 
experiments were 300 µM, 500 µM, 1000 µM and 2000 µM (see scheme 8).  
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4.2.6. Evaluation of the actions of GMG-43AC, Raceme, caffeine,         
L-Thyroxine and Eutirox® in adipogenesis  
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4.2.7. Comparison of the actions of GMG-43AC and 
PD98059 in adipogenesis 
PD98059 is a MEK-1 specific inhibitor (Prusty D et al., 2002). It  was dissolved in 
DMSO and added to the culture medium at the final concentrations of 10 µM and 30 
µM at day 2 and maintained until day 4 (see schemes below). The effect on 
adipogenesis was evaluated at day 4 or at day 10 by triglycerides quantification and/or 
by counting adipocyte cells. 
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4.2.8. Oil Red O staining and quantification of lipid accumulation in 
adipocytes 
Cells were cultured and differentiated in 6-wells or 48-wells plates on coverslips as 
described in section 2.2.1. Eight to ten days after the induction of differentiation, cells 
were rinsed twice with phosphate buffered saline (PBS), fixed with 4% fresh formalin 
in PBS for 1 hour and washed 2 times with PBS (5 min, RT). After that were stained 
with Oil Red O. Oil Red O staining is the standard technique utilized to visualize 
droplets of neutral lipid accumulated in cytoplasm (Koopman R et al., 2001). Briefly, 
this dye specifically interacts with triacylglycerol and stains droplets in red. Oil Red O 
preparation procedure and  adipocyte staining procedure used were following: 
• Prepare Oil Red O stock. Dissolve 0.5 g Oil Red O in 100 ml of isopropanol, stir 
overnight at room temperature and then filter with 0.45 µm and store at +40C. 
• Prepare Oil Red O working solution. Dilute 6 parts of the stock stain with 4 parts of 
distilled water, allow to stand for 20 min, and filter with 0.20 µm.  The stain does 
not keep, and should be made up fresh from the stock solution each time. 
• Wash wells once with 60% isopropanol (5 min, RT). 
• Let the wells dry completely. 
• Add Oil Red O working solution for 15 min (do not touch walls of the wells). 
• Remove all Oil Red O and immediately add H2O, wash with H2O 2 times and then 
wash under running tap water. 
• Take pictures if desired. 
• Remove all water and let dry. 
• Elute Oil Red O by adding 100% isopropanol, incubate about 10 min. 
• Pipet the isopropanol with Oil Red O up and down several times to be sure that all 
Oil Red O is in the solution. 
•  Transfer to 1.5 ml tubes. 
• Measure OD at 500 nm, 0.5 sec reading. 
• As blank use 100% isopropanol. As control use isopropanol from empty well 
stained as previously described. 
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The dye retained in the cells was evaluated with 2 different approaches: 
1.  by elution with 1,5 ml isopropanol for at least 10 min.  Specific optical density 
was measured at 500 nm in spectrophotometer Bio UV/VIS® Parkin Helmer 
(UK). 
2. by the counting of positive stained cells compared to all the cells indicated by 
hematoxilin (SIGMA) staining (5 min). Slides were photographed by using 
optical microscope Leica and digital camera Leica (German). Data was plotted 
reporting the percentage of positive cells as the mean of the quantification of at 
least 5 fields for each condition. 
 
4.2.9. SDS Page, Western blotting and protein detection 
Protein extraction  
For protein analysis, cells were cultured in 25cm2 Petri dishes as described before. At 
the end of the treatments, the plates were placed on ice, the media was removed and 
cells were rinsed twice with cold PBS. Protein extracts were obtained from the cells in 
RIPA buffer. Samples were incubated on ice for 30 min and centrifuged at 13,200 rpm 
at 40C for 20 min. After that the supernatants were collected. Protein concentration was 
measured at 595 nm by the Bradford method (Quick Start™ Bradford Protein Assay, 
BIO-RAD) using a spectrophotometer (MPT Reader DV990BVG).  
 
Protein sample preparation for electrophoresis 
60 μg of cell lysate was precipitated with 100% TCA (trichloroacetic acid) for 4 h at 
40C. After that samples were centrifuged at 13,200 rpm at 40C for 20 min. After that the 
supernatans were removed and pellets were washed with cold acetone at 10,000 rpm at 
40C for 5 min. Pellets were re-suspended SDS sample buffer 4X (INVITROGEN) 
containing 5% 2-β mercaptoethanol (70mM). In the case of TCA precipitation, 
Tris buffer is sometimes added to adjust pH if TCA residues are still present in sample 
resuspension. The samples are boiled for 5 min to fully denature the proteins and loaded 
onto the gel. 
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SDS Page 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is the most 
common analytical technique used to separate and characterize proteins, using a 
discontinuous polyacrylamide gel as support medium and SDS to denature the proteins. 
SDS (also called lauryl sulfate) is an anionic detergent bound by a polypeptide chain in 
proportion to its relative molecular mass. The negative charges on SDS destroy most of 
the complex structure of proteins, and are strongly attracted toward an anode in an 
electric field. Polyacrylamide gels restrain larger molecules from migrating as fast as 
smaller molecules. Because the charge-to-mass ratio is nearly the same among SDS-
denatured polypeptides, the final separation of proteins is dependent almost entirely on 
the differences in relative molecular mass of polypeptides. In a gel of uniform density 
the relative migration distance of a protein (Rf) is negatively proportional to the log of 
its mass. If proteins of known mass are run simultaneously with the unknowns, the 
relationship between Rf and mass can be plotted, and the masses of unknown proteins 
estimated. Protein separation by SDS-PAGE can be used to estimate relative molecular 
mass, to determine the relative abundance of major proteins in a sample, and to 
determine the distribution of proteins among fractions. Acrylamide is the material of 
choice for preparing electrophoretic gels to separate proteins by size. Acrylamide mixed 
with bis-acrylamide forms a cross-linked polymer network when the polymerizing 
agent, ammonium persulfate, is added. The ammonium persulfate (AP) produces free 
radicals faster in the presence of TEMED (N,N,N,N'-tetramethylenediamine). The size 
of the pores in a gel is inversely related to the amount of acrylamide used. Very large 
polypeptides cannot penetrate far into a gel and thus their corresponding bands may be 
too compressed for resolution. Polypeptides below a particular size are not restricted at 
all by the gel, and regardless of mass they all move at the same pace along with the 
tracking dye. Gel concentration (%T) should be selected to resolve precisely proteins of 
interest. A typical gel of 7% acrylamide composition separates polypeptides with 
molecular mass between 45 and 200 kDa. There are two types of buffer systems used in 
PAGE electrophoresis: continuous and discontinuous systems. A continuous system has 
only a single separating gel and uses the same buffer in the tanks and the gel. In a 
discontinuous system, a non-restrictive large pore gel, called stacking gel, is layered on 
top of a separating gel called resolving gel. Each gel is made with a different buffer, and 
the tank buffers are different from the gel buffers. The stacking gel has a lower 
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concentration of acrylamide (larger pore size), lower pH and a different ionic content. 
This allows the proteins to be concentrated into a tight band before entering in the 
resolving gel. The resolving gel may consist of a constant acrylamide concentration or a 
gradient of acrylamide concentration (high percentage of acrylamide at the bottom of 
the gel and low percentage at the top). A gradient gel is prepared by mixing two 
different concentrations of acrylamide solution to form a gradient with decreasing 
concentrations of acrylamide. As the gradient forms, it is layered into a gel cassette. 
This latter gel is recommended for separation of a mixture of proteins with a greater 
molecular weight range. 
In our experimental conditions, continuous gel was running under reducing and 
denaturant conditions. Gel preparation procedures and running conditions used are 
described in the following protocol: 
• Assemble glass plate sandwich using two clean glass plates and two 1-mm spacers. 
Assemble the casting frame and stand as described by manufacturer. 
• In a clean falcon, prepare the resolving gel solution, mixing the ingredients as 
described in table 2, remembering that AP and TEMED must be added at the end. 
Be careful not to generate bubbles. 
• Pour the resolving gel to a level about 1 cm from the top. Wait 1 min, then layer the 
top of the gel with distilled water (this will help the gel to solidify quickly in the 
absence of air). 
• Wait another 15-20 min for the gel to polymerize. Pour off the top layer of distilled 
water. Dry off as much of the water as possible, using absorbent paper. 
• In a clean falcon, prepare the stacking gel as described in table 2, being careful not 
to generate bubbles. 
• Pour the resolving gel till the space is full, then put in the appropriate comb. (The 
difference in the pH of the two layers is what causes the stacking of the proteins. 
Thus, if the proteins are not stacking properly check the pH of the buffers). 
• Allow the top portion to solidify and then carefully remove the comb or store at 4°C 
in humidified condition, until use. 
• Place gel in opposite side of apparatus (Mini-PROTEAN 3-Cell, Bio-Rad). 
• Slowly add 1x Running buffer. 
• Load samples and molecular weight marker. 
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• Run the gel at 60V until the blue dye overpass stacking phase, and then run it at 
110 V until the blue dye reaches the bottom or runs off. At this time, the run is 
stopped, cables removed. The gel is removed from the cassette and can be processed 
for western blotting. 
 
REAGENTS Running gel (1x) Stacking gel (1x) 
Acrylamyde percentage 8% 10% 3% 
dH2O 6,75 ml 5,85 ml 3,3 ml 
Lower Buffer pH=8.8 4,5 ml 4,5 ml --- 
Upper Buffer pH=6.8 --- --- 1,3 ml 
40% acrylamide/bis-
acrylamide solution 
3,6 ml 4,5 ml 380 µl 
TEMED 15 µl 15 µl 5 µl 
AP (10%) 150 µl 150 µl 50 µl 
Table 2. Resolving and Stacking gel solution recipes. 
AP: ammonium persulfate (AP); TEMED: N,N,N,N'-tetramethylenediamine 
 
Western blotting and protein detection  
The term “blotting” refers to the transfer of biological samples from a gel to a 
membrane and their subsequent detection on the surface of the membrane. Western 
blotting was introduced by Towbin and colleagues [1989] and is now a routine 
technique for protein analysis. The specificity of the antibody-antigen interaction 
enables a single protein to be identified in the midst of a complex protein mixture. 
Western blotting is commonly used to identify a specific protein in a complex mixture 
and to obtain qualitative and semiquantitative data about that. The first step in a western 
blotting procedure is to separate the macromolecules using gel electrophoresis. 
Following electrophoresis, the separated molecules are transferred onto a second matrix, 
generally a nitrocellulose membrane. Next, the membrane is blocked to prevent any 
nonspecific binding of antibodies to the surface of the membrane. The transferred 
protein is completed with an enzyme-labeled antibody as a probe. An appropriate 
substrate is then added to the enzyme and together they produce a detectable product 
such as a chromogenic or fluorogenic precipitate on the membrane for colorimetric or 
MATERIALS AND METHODS 
46 
 
fluorimetric detection, respectively. The most sensitive detection methods use a 
chemiluminescent substrate that, when combined with the enzyme, produces light. This 
output can be captured using film, a CCD camera or a phosphorimager designed for 
chemiluminescent detection. Whatever substrate is used, the intensity of the signal 
correlates with the abundance of the antigen on the blotting membrane. In our 
experimental procedure, western blotting and protein detection protocols are the 
following: 
• Cut a piece of nitrocellulose membrane (BIO-RAD). Wet the membrane in dH2O.  
• Pre-wet the sponges, filter papers (slightly bigger than gel) in 1x Transfer buffer. 
Assemble sandwich (sponge-paper-gel-membrane-paper-sponge) for the 
electroblotting apparatus (Mini Trans-Blot Electrophoretic Transfer Cell, Bio-Rad). 
• Transfer for 1 hr at 100 V with a cold pack and prechilled buffer. 
• After transfer is complete, turn off power supply and remove cathode plate of 
blotter. Remove transfer membrane and cut lower right corner of membrane to mark 
orientation of gel.  
• Staining the membrane with Ponceau’s dye and the gel with Coomassie Blue dye to 
verify the correct transfer. 
• Remove Ponceau’s staining, washing the membrane with dH2O. 
• Block the nitrocellulose membrane in TBS with 0,05% Tween-20 (v/v) (T-TBS), 
containing 5% slim milk (w/v) for at least 60 min on a rocking platform. 
• Wash the nitrocellulose membrane 3 times in T-TBS for 10 min each on a rocking 
platform. 
• Incubate the nitrocellulose membrane on a rocking platform with primary antibody 
diluted in T-TBS, overnight at 4°C. 
• Wash the nitrocellulose membrane 3 times in T-TBS for 10 min each on a rocking 
platform. 
• Incubate with secondary antibody horseradish peroxidase-conjugate diluted in T-
TBS for 60-90 min on a rocking platform at room temperature. 
• Wash the nitrocellulose membrane 3 times in T-TBS for 10 min each on a rocking 
platform.  
• Wash the nitrocellulose membrane once in TBS to remove the excess of tween. 
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• Detect proteins by means of an enhanced chemiluminescence detection system 
(ECLTM, Pierce). 
• After incubation of 5 min with ECL, blots are placed in a sheet protector and 
exposed to Kodak X-Omat Blue Film (Blue X-ray Film) (Perkin Elmer) for different 
times. Several exposures allow better densitometric analysis. 
• Autoradiography films are automated processed with an Automated x-ray film 
developer (Kodak M35A X-OMAT processor). 
Primary antibodies used in experimental procedures: 
• anti-MEK1/2 (dilution 1:1000 in T-TBS 0.05%) (Cell Signaling); 
•  anti-phopsho-MEK1/2 (dilution 1:1000 in T-TBS 0.05%) (Cell Signaling); 
•  anti-p42/44 MAPK (dilution 1:1000 in T-TBS 0.05%) (Cell Signaling);  
• anti-phospho-p42/44 MAPK (ERK1/2) (dilution 1:1000 in T-TBS 0.05%) (Cell 
Signaling);  
• anti-peroxisome proliferator-activated receptor-γ (PPARγ) (dilution 1:1000 in T-
TBS 0.05%) (Cell Signaling);  
• anti-adipocyte fatty acid-binding protein 4 (FABP-4) (dilution 1:1000 in T-TBS 
0.05%) (Cell Signaling); 
• anti-phospho peroxisome proliferator-activated receptor-γ (pPPARγ) (dilution 
1:2.5 µg/ml  in T-TBS 0.05%) (ABCAM);  
• anti-RhoA (dilution 1:200 in T-TBS 0.05%) (Santa Cruz);  
• anti-β-actin (dilution 1:1000 in T-TBS 0.05%) (SIGMA).  
 
Secondary antibodies used in experimental procedures: 
1. anti rabbit IgG-HRP (dilution 1:10.000 in T-TBS 0.05%) 
(Chemicon International). 
2. anti mouse IgG-HRP (dilution 1:5.000 in T-TBS 0.05%) 
(Chemicon International). 
 
Nitrocellulose membrane stripping 
After visualizing protein of interest, it is possible to strip off the first set of protein 
probes so that different proteins on the blot may be detected using a second set of 
specific probes. When possible, this technique saves the time and resources that would 
be necessary to electrophorese another sample and transfer it to new sheet of 
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membrane. Stripping generally involves soaking the blot in a buffer that is sufficiently 
harsh to dissociate the affinity interactions between antibodies and the target sample 
protein that was transferred to the membrane.  
In our experimental condition, the stripping protocol consists in: 
• Wash abundantly the nitrocellulose membrane with T-TBS for 20 min on a 
rocking platform. 
• Incubate the membrane with Restore Plus Western Blot Stripping Buffer (Thermo 
Scientific) for 10 min at room temperature on a rocking platform.  
• Wash abundantly the nitrocellulose membrane with T-TBS for 20 min on a 
rocking platform. 
• Return to membrane blocking and primary antibody incubation as previously 
described. 
 
Densitometric analysis 
Exposures of the same membrane for different times were acquired using GelDocTM 
image capture system (Bio-Rad), following Manufacturer’s instructions. The 
autoradiograms were quantified using Quantity OneTM and Image J software. The data 
were then analyzed with suitable statistic methods.  
 
 
Polyacrylamide gel staining 
After western blotting procedure, gel staining allows to verify the correct loading of 
protein samples and the correct protein transfer to nitrocellulose membrane. A 
commonly used stain for detecting proteins in polyacrylamide gels is 0.1% Coomassie 
Blue dye in 50% methanol, 10% glacial acetic acid. Acidified methanol precipitates 
the proteins. Staining is usually performed overnight on a rocking platform. The dye 
penetrates the entire gel, and sticks permanently to the proteins. Excess dye is washed 
out by destaining procedure with acetic acid/methanol washes on a rocking platform. 
Destaining in two steps (first using 50% methanol, 10% acetic acid for 1-2 hours, and 
then using 7% methanol, 10% acetic methanol) provided a better efficiency. Finally, 
gels can be dried or photographed for later analysis. 
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4.2.10. Confocal microscopy  
Confocal microscopy offers several 
advantages over conventional 
optical microscopy, including 
controllable depth of field, the 
elimination of image degrading 
out-of-focus information, and the 
ability to collect serial optical 
sections from thick specimens. The 
key to the confocal approach is the 
use of spatial filtering to eliminate 
out-of-focus light or flare in 
specimens that are thicker than the 
plane of focus. In recent years, 
there has been a tremendous 
explosion in the popularity of confocal microscopy, due in part to the relative ease with 
which extremely high-quality images can be obtained from specimens prepared for 
conventional optical microscopy. In a conventional widefield microscope, the entire 
specimen is bathed in light from a mercury or xenon source, and the image can be 
viewed directly by eye or projected onto an image capture device or photographic film. 
In contrast, the method of image formation in a confocal microscope is fundamentally 
different. Illumination is achieved by scanning one or more focused beams of light, 
usually from a laser or arc-discharge source, across the specimen. This point of 
illumination is brought to focus in the specimen by the objective lens, and laterally 
scanned using some form of scanning device under computer control. The sequences of 
points of light from the specimen are detected by a photomultiplier tube (PMT) through 
a pinhole (or in some cases, a slit), and the output from the PMT is built into an image 
and displayed by the computer (Fig. 11). Although unstained specimens can be viewed 
using light reflected back from the specimen, they usually are labelled with one or more 
fluorescent probes.  
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Fig. 11 Confocal microscopy image of actin 
immunostaining. Actin staining was performed in 3T3-L1 
cells, previously fixed on slide with paraformaldehyde. In 
green, actin labelling; in blue, nuclei staining with DAPI 
dye. Immunofluorescence image assessed with confocal 
microscopy TSC SP2 Leica. 
 
 
 
 
 
 
        
  
Specimen Preparation and Imaging  
The procedures for preparing and 
imaging specimens in the confocal 
microscope are largely derived from 
those that have been developed over 
many years for use with the 
conventional wide field microscope. 
In the biomedical sciences, a major 
application of confocal microscopy 
involves imaging either fixed 
(Fig. 11) or living cells and tissues 
that have usually been labelled with 
one or more fluorescent probes. A 
large number of fluorescent probes 
are available that, when incorporated 
in relatively simple protocols, specifically stain certain cellular organelles and 
structures. Among the plethora of available probes are dyes that label nuclei, the Golgi 
apparatus, the endoplasmic reticulum, and mitochondria, and also dyes such as 
fluorescently labelled phalloidins that target polymerized actin in cells. Regardless of 
the specimen preparation protocol employed, a primary benefit of the way in which 
confocal microscopy is carried out is the flexibility in image display and analysis that 
results from the simultaneous collection of multiple images, in digital form, into a 
computer.  
 
Critical aspects of Confocal microscopy 
Quantitative three-dimensional imaging in fluorescence microscopy is often 
complicated by artefacts due to specimen preparation (e.g. autofluorescence problems, 
retractile structures presence, presence or absence of highly stained structures, 
immersion oil, coverslip thickness etc.), controllable and uncontrollable experimental 
variables, or configuration problems with the microscope (e.g. optical component 
alignment, objective magnification, bleaching artefacts, aberrations, quantum 
efficiency, and the specimen embedding medium). 
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In our experimental conditions, slides were photographed using a 40x objective lens and 
1x zoom (Leica, Wetzlar, Germany) with confocal microscope Leica SP2 microscope 
with He/Kr and Ar lasers (Leica).   
 
Immunofluorescence in 3T3-L1 cells 
For all immunofluorescence experiments, cells were grown and differentiated in 
chamber-slides (Lab-Tek®) or onto glass coverslips as described before. Then cells were 
fixed with 2% (for 10 min) and 4% (successive 10 min) paraformaldehyde in PBS. 
After cell fixation, the protocol used is the following: 
• Wash three times with PBS for 5 min.  
• Incubate in saturation solution consists of 4% bovine serum albumin (BSA), 
0.3% Triton X-100 in PBS pH=7.5 for 40 min to block unspecific binding of the 
antibodies. 
• Incubate in 1:10 saturation solution to permeabilize the cell membranes, 20 min at 
room temperature.  
• Incubate with primary antibody in 1:10 saturation solution, over night at 40C. 
• Wash three times with PBS for 5 min.  
• Incubate with secondary antibody in 1:10 saturation solution, 60 min at room 
temperature.  
• Wash three times with PBS for 5 min.  
• Incubate in 0.2 mg/ml 4’,6’-diamidino-2-phenyl-indole (DAPI) for 2 min.  
• Wash two times with PBS for 10 min.  
• Mount in Fluorsave (Chemion).  
 
Primary antibodies: 
• Anti-PPARγ (dilution 1:200, Cell Signaling) 
• Anti-C/EBPα (dilution 1:50, Cell Signaling) 
• Anti-FABP-4 (diluition 1:200, Cell Signaling) 
• Anti-Leptin (dilution 5 µg/ml, ABCAM) 
• Anti-C/EBPβ (dilution 1/200, Santa Cruz) 
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• Anti-C/EBPδ (dilution 1/200, Santa Cruz) 
• Anti- RhoA (dilution 1/200, Santa Cruz) 
Labelled secondary antibodies: 
• Alexa Fluor® 488 donkey anti- Rabbit IgG (H+L) (INVITROGEN)  
• Alexa Fluor® 546 Goat Anti-Rabbit IgG (H+L) (INVITROGEN) 
• Alexa Fluor® 546 Donkey Anti-Goat IgG (H+L) (INVITROGEN)  
 
 
Actin immunofluorescent labelling in 3T3-L1 cells 
The phallotoxin had been isolated in 1937 from the deadly Amanita phalloides 
mushroom by Feodor Lynen and coll. The phallotoxin is bicyclic peptide that differ by 
two amino acid residues. It can be used interchangeably in most applications and bind 
competitively to the same sites in F-actin. Fluorescent phallotoxin stains F-actin at 
nanomolar concentrations, this providing convenient probes for labelling, identifying, 
and quantitating F-actin in tissue sections or cell cultures. It has been reported that 
phallotoxins are unable to bind to monomeric G-actin.  
For these experiments, 3T3-L1 cells were grown and differentiated onto glass coverslips 
as previously described. Cells were fixed in 3.7% formaldehyde solution in PBS for 10 
min at room temperature and then permeabilized with a cold solution of acetone (-200C) 
for 5 min. 
Preparing the stock solution: 
• The vial contents should be dissolved in 1.5 mL methanol to yield a final 
concentration of 200 units/mL, which is equivalent to approximately 6.6 µM. 
One unit of phallotoxin is defined as the amount of material used to stain one 
microscope slide of fixed cells and is equivalent to 5 µL of methanolic stock 
solution for the fluorescent phallotoxins. 
• Dilute 5 µL methanolic stock solution into 200 µL PBS for each coverslip to be 
stained. To reduce nonspecific background staining with these conjugates, add 
1% BSA to the staining solution. 
MATERIALS AND METHODS 
53 
 
When staining more than one coverslip, adjust volumes accordingly. For a stronger 
signal, use 2 or 3 units per coverslip. 
• Place the staining solution on the coverslip for 20 minutes at room temperature. To 
avoid evaporation, keep the coverslips inside a covered container during the 
incubation. 
• Wash two or more times with PBS. 
• Incubate in 0.2 mg/ml 4’,6’-diamidino-2-phenyl-indole (DAPI) for 2 min.  
• Wash two times with PBS for 10 min.  
• Mount in Fluorsave (Chemion). 
 
 
4.2.11. RNA extraction 
Real-time RT-PCR analysis 
For these experiments, cells were grown and differentiated in 25cm2 Petri dishes as 
described before. Total RNA was isolated by using TRI Reagent® (SIGMA) in 
accordance with the manufacturer’s instructions. In briefly, the procedure used was the 
following: 
• Add 1 ml of TRI Reagent directly on the culture dish. After addition of the reagent, 
the cell lysate should be passed several times through a pipette to form a 
homogenous lysate.   
• Phase Separation: To ensure complete dissociation of nucleoprotein complexes, 
allow samples to stand for 5 minutes at room temperature. Add 0.2 ml of chloroform 
per ml of TRI Reagent used. Cover the sample tightly, shake vigorously for 
15 seconds, and allow to stand for 15 min at room temperature. Centrifuge the 
resulting mixture at 12,000 x g for 15 minutes at 4°C.  
Centrifugation separates the mixture into 3 phases: a red organic phase (containing 
protein), an interphase (containing DNA), and a colourless upper aqueous phase 
(containing RNA). 
• Transfer the aqueous phase to a fresh tube and add 0.5 ml of isopropanol per ml of 
TRI Reagent used in Sample Preparation and mix. Allow the sample to stand for 10 
min at room temperature. Centrifuge at 12,000 x g for 10 min at 4°C. The RNA 
precipitate will form a pellet on the side and bottom of the tube. 
MATERIALS AND METHODS 
54 
 
• Remove the supernatant and wash the RNA pellet by adding 1 ml of 75% ethanol 
per 1 ml of TRI Reagent used in Sample Preparation. Vortex the sample and then 
centrifuge at 7,500 x g for 5 min at 4°C. 
• Briefly dry the RNA pellet for 5–10 minutes by air-drying. Do not let the RNA 
pellet dry completely, as this will greatly decrease its solubility. Add an appropriate 
volume of 0.5% SDS water, or to the RNA pellet. To facilitate dissolution, mix by 
repeated pipetting with a micropipette at 55–60 °C for 10 min. 
The RNA quality was verify by running it onto 1% agarose gel and the amount of 
RNA in the sample was quantified spectrophotometrically. The ratio between 
A260/A280 was calculated to verify RNA purity. 100 ng/sample was used for cDNA 
synthesis.  
 
Degradation of genomic DNA and reverse transcription-PCR (RT-PCR) 
The degradation of contaminating genomic DNA from RNA samples was performed 
with DNase I (RNase-free) (New England BioLabs) according to manufacturer’s 
instructions. In briefly, the procedure used was the following: 
• Resuspend 1 µg RNA in 1X DNase I Reaction Buffer to a final volume of 10 µ. 
• Add 1 unit of DNase I, mix thoroughly and incubate at 370C for 10 min.  
• Add 0.5 M EDTA to a final concentration of 5 mM. EDTA should be added to a 
final concentration of 5 mM to protect RNA from being degraded during enzyme 
inactivation. 
• Heat inactivate at 750C for 10 min. 
The synthesis of single-strand cDNA was carried out on 1 μg of RNA template, using 
iScript™ Reverse Transcription Supermix for RT-qPCR (BIO-RAD) following the 
manufacturer’s instructions. 
 
Component Volume per reaction 
5X iScript reverse transcription supermix 4 µl 
RNA template (1 µg total RNA) 11 µl 
Nuclease-free water 5 µl 
Total volume 20 µl 
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Reaction protocol: 
 
Priming 5 min at 250C 
Reverse transcription 30 min at 420C 
RT inactivation 5 min at 850C 
 
Retrotrascription samples are stored at -20°C, until their use for real time RT-PCR. 
 
Real Time RT-PCR  
Real-time RT-PCR quantities the initial amount of the template most specifically, 
sensitively and reproducibly, and is a preferable alternative to other forms of 
quantitative RT-PCR that detect the amount of final amplified product at the end-point 
(Freeman WM et al., 1999). Real-time PCR monitors the fluorescence emitted during 
the reaction as an indicator of amplicon production during each PCR cycle as opposed 
to the endpoint detection (Higuchi R et al., 1993), eliminating post-PCR processing of 
PCR products. This helps to increase throughput and to reduce the chances of carryover 
contamination. In comparison to conventional RT-PCR, real-time PCR also offers a 
much wider dynamic range of up to 107-fold (compared to 1000-fold in conventional 
RT-PCR). The real-time PCR system is based on the detection and quantitation of a 
fluorescent report (Livak KJ et al., 1995). This signal increases in direct proportion to 
the amount of PCR product in a reaction. By recording the amount of fluorescence 
emission at each cycle, it is possible to monitor the PCR reaction during exponential 
phase where the first significant increase in the amount of PCR product correlates to the 
initial amount of target template. The higher the starting copy number of the nucleic 
acid target, the sooner a significant increase in fluorescence is observed. Currently four 
different chemistries, TaqMan®, Molecular Beacons, Scorpions® and SYBR® Green 
(BIO-RAD), are available for real-time PCR. All of these chemistries allow detection of 
PCR products via the generation of a fluorescent signal. TaqMan probes, Molecular 
Beacons and Scorpions depend on Förster Resonance Energy Transfer (FRET) to 
generate the fluorescence signal via the coupling of a fluorogenic dye molecule and a 
quencher moiety to the same or different oligonucleotide substrates. SYBR Green is a 
fluorogenic dye that exhibits little fluorescence when in solution, but emits a strong 
fluorescent signal upon binding to double-stranded DNA. The threshold cycle or Ct 
value (Fig. 12) is the point when the system begins to detect the increase in the signal 
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associated with an exponential 
growth of PCR product during 
the log-linear phase. This 
phase provides the most useful 
information about the reaction 
and the slope of the log-linear 
phase is a reflection of the 
amplification efficiency. The 
efficiency (Eff) of the reaction 
can be calculated by the formula: Eff=10(-1/slope) – 1. The efficiency of the PCR should 
be 90 - 100% (–3.6 > slope > –3.1). A number of variables can affect the efficiency of 
the PCR. These include length of the amplicon, secondary structure and primer quality. 
The Ct is an important parameter for quantitation. The higher the initial amount of 
genomic DNA, the sooner accumulated product is detected in the PCR process, and the 
lower is the Ct value. The threshold should be placed above any baseline activity and 
within the exponential increase phase. Some software allows determination of the cycle 
threshold (Ct) by a mathematical analysis of the growth curve. This provides better run-
to-run reproducibility. Two strategies are commonly employed to quantify the real-time 
RT-PCR data: the standard curve method (absolute quantification) and the 
comparative Ct method (relative quantification). 
In the standard curve method, a standard curve is first constructed from an RNA of 
known concentration. This curve is then used as a reference standard for extrapolating 
quantitative information for mRNA targets of unknown concentrations, thus generating 
absolute copy number data. In addition to RNA, other nucleic acid samples can be used 
to construct the standard curve, including purified plasmid dsDNA, in vitro generated 
ssDNA or any cDNA sample expressing the target gene. Spectrophotometric 
measurements at 260 nm can be used to assess the concentration of these DNAs, which 
can then be converted to a copy number value based on the molecular weight of the 
sample used. However, cDNA plasmids are the preferred standards for standard curve 
quantitation. The comparative Ct method involves comparing the Ct values of the 
samples of interest with a control or calibrator such as a non-treated sample or RNA 
from normal tissue. The Ct values of both the calibrator and the samples of interest are 
normalized to an appropriate endogenous housekeeping gene. The comparative Ct 
method is also known as the 2–ΔΔCt method (Livak KJ et al., 2001), where 
 
Fig. 12 Real time RT-PCR curves and Ct values. 
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ΔΔCt = ΔCt,sample - ΔCt,reference. ΔCt,sample is the Ct value for any sample normalized to the 
endogenous housekeeping gene and ΔCt, reference is the Ct value for the calibrator also 
normalized to the endogenous housekeeping gene. For the ΔΔCt calculation to be valid, 
the amplification efficiencies of the target and the endogenous reference must be 
approximately equal. This can be established by looking at how ΔCt varies with 
template dilution. If the plot of cDNA dilution versus delta Ct is close to zero, it implies 
that the efficiencies of the target and housekeeping genes are very similar. This 
quantification method is described in the Applied Biosystems User Bulletins #2 and #5. 
Relative gene expression comparisons work best when the expression of the chosen 
internal control is abundant and remains constant among the samples. By using an 
invariant endogenous control as an active reference, quantitation of an mRNA target can 
be normalised for differences in the amount of total RNA added to each reaction. For 
this purpose, the most common choices are 18S RNA, GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) and β-actin.  
Real-time PCR requires an instrumentation platform that consists of a thermal cycler, a 
computer, optics for fluorescence excitation and emission collection, data acquisition, 
and analysis software. These machines, available from several manufacturers, differ in 
sample capacity (some are 96-well standard format, others process fewer samples or 
require specialized glass capillary tubes), method of excitation (some use lasers, others 
broad spectrum light sources with tuneable filters), and overall sensitivity.  
In our experimental conditions, Real-time PCR was performed in an MJ Opticon 2 
using iQ™ SYBR Green supermix (BIO-RAD) following the manufacturer’s 
instructions. 18S rRNA was used as reference housekeeping gene for normalization. We 
performed an analysis using the ΔΔCt, this procedure can be used since we have 
determined previously that the replication efficiencies (slopes of the calibration or 
standard curves) for the genes of interest and housekeeping gene are very close. All the 
amplification reactions were performed in duplicate. The primers were designed using 
Oligo Perfect® Designer Software (INVITROGEN). The nucleotide sequences of the 
primers were: 
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Gene Name Forward primer Reverse primer 
C/EBPβ CGCCTACCTGGGCTACCA GACAGCTGCTCCACCTTCTTC 
C/EBPδ ATACCTCAGACCCCGACAGC ATGCTTTCCCGTGTTCCTTC 
C/EBPα GAAGGTGCTGGAGTTGACCA AGGAAGCAGGAATCCTCCAA 
PPARγ GTGGGGATGTCTCACAATGC TGATCTCTTGCACGGCTTCT 
FABP-4 ACGGCCCTGCAGAACTATCT AAGGTTCACAAACGCGACAG 
Pref-1 TTTCAACAAGGAGGCTGGTG TCTAAGGGTTGCGGTGTGAG 
Leptin TGTGCACCTGAGGGTAGAGG CCCTGGACAACCTTGGAGAT 
HSL GCTTCTCCCTCTCGTCTGCT CAGACACACTCCTGCGCATA 
18S rRNA ACCGCGGTTCTATTTTGTTG GACAAATCGCTCCACCAACT 
Table 3. The nucleotide sequences of the primers used for the experiments. 
C/EBPα, β and δ, CCAAT/enhancer-binding protein; PPARγ, peroxisome 
proliferative-activated receptor, gamma; FABP-4,  fatty acid binding protein; Pref-1, 
preadipocyte factor-1; HSL, hormone-sensitive lipase; 18S rRNA, 18S ribosomal 
RNA. 18S rRNA was used as the internal control. 
 
Real Time RT PCR conditions 
Amplification reactions were performed in 96-well standard plate. Each sample was 
analysed in duplicate. Reaction mix for all primers was prepared adding 2 µl of cDNA 
sample (dilution 1:10) to the following mix: 
• 1.2 μl of primer forward (10 µM) 
• 1.2 μl of primer reverse (10 µM) 
• 10.6 μl of Dnase and Rnase free water 
• 15 μl of 2X iQ™ SYBR Green supermix  
 
Amplification conditions were:  
• 95°C for 10 min 
• 95°C for 15 sec 
• 60°C for 30 sec 
• 750C for 30 sec 
 
40 cycles 
1 cycle 
MATERIALS AND METHODS 
59 
 
4.2.12. Lipolysis measurement  
For these experiments, cells were cultured and differentiated in 96-wells as described 
before. Lipolytic activity of GMG-43AC was evaluated after 2 and 7 days of treatment 
(see scheme 1) and after 4 days of drug-induced reversion of adipogenesis process. 
Lipolysis was evaluated by measuring the amount of glycerol released into the growth 
medium. Lipolysis was assayed by means of a commercial Assay KIT for Glycerol 
Detection (Zen-Bio Inc, Research Triangle Park, NC) according to the manufacturer’s 
instructions. Briefly, glycerol released to the medium was phosphorylated by adenosine 
triphosphate (ATP) forming glycerol-1-phosphate (G-1-P) and adenosine-5’-
diphosphate (ADP) in the reaction catalyzed by glycerol kinase. G-1-P was then 
oxidized by glycerol phosphate oxidase to dihydroxyacetone phosphate (DAP) and 
hydrogen peroxide (H2O2). A quinoneimine dye was produced by the peroxidase 
catalyzed coupling of 4-aminoantipyrine (4-AAP) and sodium N-ethytl-N-(3-
sulfopropyl)m-anisidine (ESPA) with H2O2. The increase in absorbance at 540nm was 
directly proportional to glycerol concentration of the sample and was measured in 
spectrophotometer Bio UV/VIS® Parkin Helmer (UK). 
 
 
 
 
4.2.13. TUNEL assay 
The cells were cultured and differentiated on 48-wells plates on coverslips as described 
before. 3T3-L1 were fixed with 4% for 15 min paraformaldehyde in PBS. TUNEL 
(Terminal deoxynucleotidyl transferase dUTP Nick End Labeling) is a common method 
for detecting DNA fragmentation that results from apoptotic signaling cascades. It 
measures the fragmented DNA of apoptotic cells by catalytically incorporating 
fluorescin-12-dUTP at 3’-OH DNA ends using the Terminal Deoxynucleotidyl 
Transferase enzyme (rTdT). The fluorescin-12-dUTP-labeled DNA can be visualized 
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directly by fluorescence microscopy. Nuclei were visualized after 2 min incubation with 
0.2 mg/ml 4’,6’-diamidino-2-phenyl-indole (DAPI). The apoptotic cells were visualized 
using TUNEL kit (ApoTag; Chemicon, Tamecula, CA) according to a standard protocol 
supplied by the manufacturer. Slides were photographed using fluorescence microscope 
Leica and digital camera Leica (German). 
 
Statistical analysis 
All data were expressed as means ± SEM. Differences between groups were examined 
for statistical significance using the unpaired Student’s t-test. Multiple comparisons 
were analyzed by one-way analysis of variance (ANOVA) followed by Tukey post hoc 
test. Statistical significance was accepted at a level P<0.05. 
 
  
5. RESULTS  
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5.1. The differentiation protocol for 3T3-L1 cells and Oil Red O 
staining 
Adipogenesis is the process by which undifferentiated precursor cells differentiate into 
fat cells. This has become one of the most intensively studied developmental processes 
for at least two reasons: the increasing prevalence of obesity in our society has focused 
attention on many aspects of fat cell biology, and the availability of good cell culture 
models of adipocyte differentiation has permitted detailed studies not possible in other 
systems (Kui-Jin K et al., 2010). 3T3-L1 cells constitute one of the most popular in 
vitro models for the investigation of adipogenesis. These cells show fibroblast-like 
morphology with 3-4 protrusions and express receptors for growth factors such as 
insulin. Under certain stimulation, 3T3-L1 cells gradually become adipocytes and 
produce triglycerides accumulated in small and large droplets in cytoplasm (Fig.13).  
3T3-L1 preadipocytes     3T3-L1 adipocytes 
Fig. 13 3T3-L1 preadipocytes (left) and adipocytes (right). Pictures were taken with 
EVOS® microscope (AMG, USA) 
 
Studies in adipogenic cell lines have shown that the differentiation of preadipocytes into 
adipocytes is accompanied by changes in gene expression, e.g., a dramatic increase in 
the expression of the CCAAT/enhancer binding proteins C/EBPβ and C/EBPδ followed 
by the expression C/EBPα and the nuclear hormone receptor peroxisome proliferator-
activated receptor γ (PPARγ) (Rosen ED et al., 2002; Kui-Jin K et al., 2010). These 
latter factors induce gene expression changes characteristic of mature adipocytes and 
remain elevated for the life of the cell. In the present model of the transcriptional 
cascade leading to adipogenesis, C/EBPβ and C/EBPδ induce low levels of PPARγ and 
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C/EBPα, which are then able to induce each other's expression in a positive feedback 
loop that promotes and maintains the differentiated state. This model is consistent with 
gain-of-function data showing that the addition of either PPARγ or C/EBPα can 
promote adipogenesis in fibroblast cell lines (Rosen ED et. al., 2002) 
To achieve the goals proposed in this research project it was necessary to set up: a) the 
differentiation protocol for 3T3-L1 cells; b) the colorimetric technique for detecting 
adipocyte droplets, and c) the quantification assay for accumulated triglycerides. 
 
 
Fig. 14 Oil Red O staining of undifferentiated 3T3-L1 cells (top) and adipocytes (bottom). 
 
In our experimental conditions droplets of triglycerides accumulated in differentiated 
3T3-L1 cells were highly positive to the Oil Red O staining, which is shown in red in 
figure 14. The quantification of adipocytes and measurement of extracted Oil Red O at 
500 nm are reported in figure 15. 
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Fig. 15 Oil Red O staining of undifferentiated 3T3-L1 cells and adipocytes. Quantification of positive 
cells (left). Measurement of accumulated triglycerides (right). Each experimental condition was assayed 
in triplicate and the graph is referred to the means of at least eight independent experiments. Values are 
mean ± SEM. Significantly different from UNDIFF,*P<0.05, **P<0.01, ***P < 0.001. 
 
 
5.2. GMG-43AC inhibition of lipid accumulation during    3T3-L1 
differentiation in adipocyte promoting medium: 
results of scheme 1 
 
5.2.1. Effects of GMG-43AC on lipid accumulation of adipocytes 
To examine the role of GMG-43AC on adipocyte formation and lipid accumulation the 
drug was administrated to 3T3-L1 cells throughout the 10 days (see: materials and 
methods, scheme 1) and the effects were evaluated on day 10. Figure 16 shows a typical 
Oil Red O staining of lipid accumulation in differentiated adipocytes (Fig. 16, panel A). 
This process was significantly counteracted by the drug at the dosages beginning from 
500 µM (Fig. 16, panel B and C). 
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Fig. 16 (A) Oil Red O staining of adipocytes at day 10;  (B) Oil Red O staining of adipocytes treated with 
500 µM GMG-43AC at day 10 ; (C) Oil Red O staining of adipocytes treated with 1000 µM GMG-43AC 
at day 10. 
 
Figure 17 shows the total count of differentiated cells positive to Oil Red O staining 
expressed as a percentage of the total number of cells. Almost 80% of the cells were 
positive to Oil Red O staining. According to the results, low concentrations of GMG-
43AC (ranging from 0.1 µM to 300 µM) had no significant inhibitory effects on cell 
differentiation after 10 days of treatment. The inhibitory effects were observed with 
GMG-43AC concentrations of 500 µM and higher. These results were confirmed by 
measuring the absorbance at 500 nm of the triglycerides stained with Oil Red O and 
extracted from differentiated 3T3-L1 cells of the various experimental groups (Fig. 18). 
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Fig. 17 Oil Red O staining at day 10 of undifferentiated 3T3-L1 cells and adipocytes (scheme 1 of 
treatment). Percentage of positive cells in reference to total cell population. Reported values 
(mean± SEM) are the result of three independent experiments and for each experiment 5 fields were 
considered for each condition. Significantly different from DIFF, *P<0.005, **P<0.01, ***P<0.001. 
 
 
Fig. 18  Levels of accumulated triglycerides (labelled with Oil Red O) in 3T3-L1 undifferentiated cells 
and adipocytes as evidenced by quantitative absorbance at 500 nm wavelength (scheme 1 of treatment). 
Each experimental condition was assayed in triplicate and the graph is referred to the means of four 
independent experiments. Values are mean ± SEM. Significantly different from DIFF, *P<0.05, 
**P<0.01, ***P<0.001. 
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5.2.2. Effects of GMG-43AC on protein expression 
To examine the effect of GMG-43AC on expression of factors involved in adipogenesis 
regulation during the differentiation period, preadipocytes were induced to 
differentiated in induction medium with different doses of drug and harvested at 
indicated time (12 hours, 48 hours, 4 days and 10 days). Western blotting was 
performed to analyze the expression of adipocyte marker proteins such as C/EBPβ 
(CCAAT/enhancer binding protein β), C/EBPα, PPARγ (peroxisome proliferator-
activated receptor and FABP-4 (fatty acid binding protein-4). The changes of protein 
expression during differentiation were shown in figure 19. As expected, differentiation 
towards adipocytes first affected C/EBPβ. The C/EBPβ level was abundantly increased 
at 12 hours of adipogenesis stimulated in vitro by 3-isobutyl-1-methylxanthine (IBMX) 
and at 48 hours its expression began to decrease. Treatment with the doses 300 µM and 
500 µM of GMG-43AC slowed the degradation of C/EBPβ at 48 hours. On the 
contrary, the dosage 1000 µM reduced the levels of this protein starting from 48 hours 
of differentiation. 
Western blotting was also performed to evaluate the protein expression of markers 
specific for terminal differentiation phase, such as PPARγ and C/EBPα. As required, 
during the adipogenesis the levels of both of them increased and were maximal at day 
10 of differentiation. It was noticeable that the drug dose of 300 μM does not modified 
significantly expression of PPARγ and C/EBPα. While the expression of both of them 
was significantly counteracted by GMG-43AC at the higher dosages (Fig. 19). 
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Fig. 19 Western blotting analysis of molecular factors involved in adipogenesis. At the indicated time 
cells were lysed with RIPA buffer.  Sixty micrograms of total protein extracts were separated in 
denaturing SDS-PAGE and transferred onto nitrocellulose membrane. Specific antibodies were used to 
study the expression of proteins involved in adipogenesis. The experiment was repeated three time with 
similar results. 
 
 
In this study, the levels of FABP-4 protein expression were also investigated. FAPB-4 is 
a characteristic protein of mature adipocytes. As figure 20 clearly shows, after treatment 
with GMG-43AC for 10 days the levels of FABP-4 were decreased in a dose-dependent 
manner. 
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Fig. 20 Western blotting analysis of FABP-4). At the end the incubation period cells were lysed with 
RIPA buffer. Sixty micrograms of total protein extracts were separated in denaturing SDS-PAGE and 
transferred to a nitrocellulose membrane.  FABP-4 antibody was used to study the expression of proteins 
involved in adipogenesis. The experiment was repeated three time with similar results. 
 
Therefore, the phosphorylation of PPARγ in the presence of GMG-43AC was 
investigated. The results shows that pPPARγ levels decreased as well as PPARγ. 
This result suggests that GMG-43AC was not involved in the phosphorylation of 
PPARγ (Fig. 21). 
 
 
Fig. 21 Western blotting analysis of molecular factors involved in adipogenesis. At the indicated time 
cells were lysed with RIPA buffer. Sixty micrograms of total protein extracts were separated in 
denaturing SDS-PAGE and transferred onto nitrocellulose membrane. Phospho-PPARγ and PPARγ 
antibodies were used to study the expression of proteins involved in adipogenesis. The experiment was 
repeated three time with similar results. 
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The expression and localization of PPARγ and FABP-4 proteins were investigated by 
means of immunofluorescence experiments (Fig. 22 and 24). By using the same 
technique we also investigated the expression of other master proteins strictly related to 
adipogenesis such as C/EBPα  and leptin (Fig. 23 and 25).  
Briefly, 3T3-L1 were differentiated in the presence of two the most active dosages of 
GMG-43AC: 1000 µM and 2000 µM for 10 days as described before. As previously 
reported by other authors, in adipogenesis the expression of these proteins is increased 
during adipogenesis (Rosen B et al., 2006). Our results show that the levels of these 
proteins was up-regulated in our experimental condition. The exposure to GMG-43AC 
during the experimental period markedly reduced PPARγ and C/EBPα. (Fig. 22 and 23). 
As a consequence of these, the drug treatment also down-regulated FABP-4 and leptin 
expression (Fig. 24 and 25). Regarding leptin, it was noticeable that the dose of 
1000 μM of experimental drug did not reduce the number of positive cells but changed 
the intracellular distribution of the protein (Fig. 25).  
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Fig. 22 Immunofluorescence analysis of PPARγ. (A) preadipocytes; adipocytes; adipocytes treated with 
1000 µM and 2000 µM GMG-43AC for 10 days. (B)  Quantification (%) of cells expressing PPARγ in 
different experimental conditions. Higher doses of GMG-43AC abolished the expression of PPARγ. 
Reported values (mean ± SEM) are the result of three independent experiments and for each experiment 
at least 5 fields were considered for each condition. Significantly different from DIFF, *P<0.05,  
**P<0.01, ***P<0.001. 
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Fig. 23 Immunofluorescence analysis of C/EBPα. (A) preadipocytes; adipocytes; adipocytes treated 
with 1000 µM and 2000 µM GMG-43AC for 10 days. (B)  Quantification (%) of cells expressing 
C/EBPα in different experimental conditions. Higher doses of GMG-43AC abolished the expression of 
C/EBPα. Reported values (mean ± SEM) are the result of three independent experiments and for each 
experiment at least 5 fields were considered for each condition. Significantly different from DIFF, 
*P<0.05,  **P<0.01, ***P<0.001. 
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Fig. 24 Immunofluorescence analysis of FABP-4. (A) preadipocytes; adipocytes; adipocytes treated 
with 1000 µM and 2000 µM GMG-43AC for 10 days. (B)  Quantification (%) of cells expressing FABP-
4 in different experimental conditions. Higher doses of GMG-43AC abolished the expression of FABP-4. 
Reported values (mean ± SEM) are the result of three independent experiments and for each experiment 
at least 5 fields were considered for each condition. Significantly different from DIFF, *P<0.05,  
**P<0.01, ***P<0.001. 
RESULTS 
74 
 
 
 
Fig. 25 Immunofluorescence analysis of leptin. (A) preadipocytes; adipocytes; adipocytes treated with 
1000 µM and 2000 µM GMG-43AC for 10 days. (B)  Quantification (%) of cells expressing leptin in 
different experimental conditions. Higher doses of GMG-43AC abolished the expression of leptin. 
Reported values (mean ± SEM) are the result of three independent experiments and for each experiment 
at least 5 fields were considered for each condition. Significantly different from DIFF, *P<0.05,  
**P<0.01, ***P<0.001. 
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To examine whether GMG-43AC changes expression of C/EBPβ and C/EBPδ, we 
differentiated 3T3-L1 cells in the presence of the drug (300, 500, 1000 and 2000 µM) 
for the initial 48 hours. The isoforms C/EBPβ and C/EBPδ are two critical markers for 
the early phase of differentiation and are dramatically up-regulated within the first hours 
after induction of adipogenesis by IBMX and DEX respectively (see part 1.3.1). They 
are known to have crucial role in the regulation of PPARγ and C/EBPα expression 
(Kawaji A et al., 2010). The expression of C/EBPβ and C/EBPδ proteins after exposure 
to GMG-43AC was investigated by means of immunofluorescence. 
Our results show that the expression of these proteins was increased in our experimental 
condition (Fig. 26 and 28). The exposure to GMG-43AC during the initial 48 hours of 
adipogenesis markedly reduced C/EBPβ levels in a dose-dependent manner with 
the exception of the dose 300 µM (Fig. 26 and 27). Interestingly, this dosage slowed 
down the degradation of C/EBPβ at 48 hours of differentiation. Data is comparable to 
that obtained by using western blotting technique (Fig. 19). 
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Fig. 26 Immunofluorescence analysis of C/EBPβ. Preadipocytes; adipocytes; adipocytes treated with 
300, 500, 1000 and 2000 µM GMG-43AC for the initial 48 hours of differentiation. 
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Fig. 27 Immunofluorescence analysis of C/EBPβ. Quantification (%) of cells expressing C/EBPβ in 
different experimental conditions. Reported values (mean ± SEM) are the result of three independent 
experiments and for each experiment at least 5 fields were considered for each condition. Significantly 
different from DIFF, *P<0.05, **P<0.01, ***P < 0.001. 
 
We also evaluated the effects of GMG-43AC on the expression of C/EBPδ. Our results 
show that exposure to GMG-43AC markedly reduced the levels of this protein at 
the lower dose of 300 μM. Contrastingly, further doses did not influence the number of 
C/EBPδ - positive cells after 48 hours of treatment (Fig. 28 and 29). 
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Fig. 28  Immunofluorescence analysis of C/EBPδ. Preadipocytes; adipocytes; adipocytes treated with 
300, 500, 1000 and 2000 µM GMG-43AC for the initial 48 hours of differentiation. 
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Fig. 29 Immunofluorescence analysis of C/EBPδ. Quantification (%) of cells expressing C/EBPδ in 
different experimental conditions. Reported values (mean ± SEM) are the result of three independent 
experiments and for each experiment at least 5 fields were considered for each condition. Significantly 
different from DIFF, *P<0.05, **P<0.01, ***P<0.001. 
 
 
5.2.3. Effects of GMG-43AC on adipogenic transcription factors 
The effect of GMG-43AC on the expression of preadipocyte and adipogenic 
transcription factors was also performed by means of real time RT-PCR. In particular, 
mRNA levels were quantified in several time points of adipogenesis: 12 hours, 
48 hours, 4 days and 10 days. To this purpose, quantitative real time RT-PCR was 
performed in duplicate and a negative control was also included in each 96-well plate. 
Results obtained were quantified with comparative Ct method, using 
18S ribosomal RNA as reference and the data were expressed as n-fold the calibrator by 
using the 2-∆∆Ct (undifferentiated cells for Pref-1 mRNA; differentiated cells for the 
other mRNA). 
First, we analyzed mRNA levels of C/EBPβ and C/EBPδ. Our results show that 
exposure to GMG-43AC significantly reduced mRNA levels of C/EBPβ by the drug at 
the dosages beginning from 500 µM at 12 hours of adipogenesis. However, 
the expression of C/EBPβ was not significantly affected at the lower dose of 300 μM 
(Fig. 30, panel A). Differently, at 48 hours of adipose differentiation, the drug dose of 
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300 μM reduced mRNA levels of C/EBPβ (P<0.001) and further doses were no longer 
as effective in the reduction of mRNA levels of C/EBPβ as at 12 hours (Fig. 30, 
panel B). We suppose that the lower dosages of GMG-43AC need more time to become 
effective in lowering the mRNA levels of C/EBPβ. In contrast, the higher doses faster 
reduce the levels of mRNA but their efficiency is short-lived. We think that it could be 
a saturation phenomenon or compensatory effect. 
Fig. 30 Effects of GMG-43AC on the expression of C/EBPβ during adipocyte differentiation.    
3T3-L1 cells were treated with GMG-43AC (300, 500, 1000, 2000 µM) for the initial (A) 12 hours or 
(B) 48 hours of adipogenesis. Data are the mean ± SEM of at least four determinations for each time 
point. Significantly different from DIFF C/EBPβ, *P<0.05, **P<0.01, ***P<0.001. 
 
We further examined the effect of GMG-43AC on the expression of C/EBPδ mRNA. 
Our results show that after 12 hours of treatment with GMG-43AC there was no 
significant changes in the expression of C/EBPδ (Fig. 31, panel A). Differently, at 
48 hours the dose of 300 μM slightly reduced expression of C/EBPδ (P<0.05), but 
interestingly, the dosage of 1000 µM significantly raised mRNA levels (P<0.01) 
(Fig. 31, panel B). Further doses had no significant effects on the expression of mRNA 
levels of C/EBPδ (Fig. 31, panel B). Together, these results suggest that the dose of 300 
µM of GMG-43AC may need more time to decrease the expression of C/EBPδ. 
Differently, we suspect that it could be some compensatory or saturation phenomenon 
in case of the dosage 1000 µM of the drug. 
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Fig. 31 Effects of GMG-43AC on the expression of C/EBPδ during adipocyte differentiation.     
3T3-L1 cells were treated with GMG-43AC (300, 500, 1000, 2000 µM) for the initial (A) 12 hours or 
(B) 48 hours of adipogenesis. Data are the mean ± SEM of at least four determinations for each time 
point. Significantly different from DIFF C/EBPδ, *P<0.05, **P<0.01, ***<0.001. 
 
We then examined the expression of PPARγ and C/EBPα, late adipogenic markers, 
which are crucial for adipocyte differentiation (Kim KJ et al., 2010). 
Our results show that exposure to GMG-43AC markedly reduced mRNA levels of 
PPARγ at the dose of 2000 μM at 48 hours of differentiation process and this effect was 
maintained until the end of the adipogenesis (Fig. 32, panels A-C). GMG-43AC at 
1000 µM decreased the mRNA levels starting from 4th day of differentiation. 
Interestingly, after 4 days of experiment the dose 500 µM significantly abolished 
(P<0.001) the expression of PPARγ, however, this effect was not maintained at the end 
of adipocyte differentiation (Fig. 32, panels B and C).  
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Fig. 32 Effects of GMG-43AC on the expression of PPARγ during adipocyte differentiation. 3T3-L1 
cells were treated with GMG-43AC (300, 500, 1000, 2000 µM) for (A) 48 hours, (B) 4 days or 
(C) 10 days of adipogenesis. Data are the mean ± SEM of at least four determinations for each time point. 
Significantly different from DIFF PPARγ2 , *P<0.05, **P<0.01, ***P<0.001. 
 
Therefore we evaluated the effects of GMG-43AC on the mRNA levels of C/EBPα 
from 48 hours to 10 days of differentiation. As shown in Figure 33, the experimental 
drug markedly inhibited the expression of this gene at the dosages 1000 µM and 
2000 µM. This effect was maintained until day 10 of the adipogenesis. As in the case of 
PPARγ, after 4 days of experiment the dose 500 µM significantly abolished (P<0.001) 
the mRNA levels of C/EBPα, however, this effect was not sustained at the end of 
adipocyte differentiation (Fig. 33, panels B and C). Interestingly, the dosage of 300 µM 
significantly raised mRNA levels at 10 day (Fig 33, panel C).  
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Fig. 33 Effects of GMG-43AC on the expression of C/EBPα during adipocyte differentiation.    
3T3-L1 cells were treated with GMG-43AC (300, 500, 1000, 2000 µM) for (A) 48 hours, (B) 4 days or 
(C) 10 days of adipogenesis. Data are the mean ± SEM of at least four determinations for each time point. 
Significantly different from DIFF C/EBPα, *P<0.05, **P<0.01, ***P<0.001. 
 
At days 4 and 10 of adipogenesis RT-PCR was performed to analyze the mRNA levels 
of FABP-4 and leptin that were known to be expressed in mature adipocytes (Xing Y et 
al., 2010). As might be expected, the genes encoding these proteins were expressed in 
the terminal phase of adipogenesis. FABP-4 and leptin were not critical to 
the differentiation process, but occurred as a result of adipocyte differentiation 
(Cowhed RM et al., 1999). 
In our experimental conditions the mRNA levels of FABP-4 and leptin were down-
regulated in a dose-dependent manner with all tested doses of GMG-43AC (Fig. 34 and 
35). Data is comparable to that of immunofluorescence (Fig. 23 and 24). 
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Fig. 34 Effects of GMG-43AC on the expression of FABP-4 during adipocyte differentiation.     
3T3-L1 cells were treated with GMG-43AC (300, 500, 1000, 2000 µM) for (A) 4 days or (B) 10 days of 
adipogenesis. Data are the mean ± SEM of at least four determinations for each time point. Significantly 
different from DIFF FABP-4, *P<0.05, **P<0.01, ***P<0.001. 
 
 
Fig. 35 Effects of GMG-43AC on the expression of leptin during adipocyte differentiation. 3T3-L1 
cells were treated with GMG-43AC (300, 500, 1000, 2000 µM) for (A) 4 days or (B) 10 days of 
adipogenesis. Data are the mean ± SEM of at least four determinations. Significantly different from DIFF 
leptin, *P<0.05, **P<0.01, ***P<0.001. 
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To further investigate the effects of GMG-43AC on the initial phase of adipogenic 
differentiation, the expression of mRNA levels of Pref-1 was examined. Pref-1 is 
abundantly expressed in preadipocytes and disappears in adipocytes. Moreover, it is an 
inhibitor of adipocyte differentiation (Gao Y et al., 2008). As was shown by Sul, 
dexamethasone inhibits the transcription of protein Pref-1 (Sul HS, 2009).  
As figure 36 made clear, the expression of Pref-1 was significantly reduced during the 
period of adipogenesis. At 12 hours of differentiation all doses of GMG-43AC appeared 
to potentiate the down-regulation effect of dexamethasone (Fig. 36, panel A). After 
the initial 48 hours, the dosage of 2000 µM started to be significant in increasing 
the mRNA levels of this gene (Fig. 36, panels B-D). 
 
 
Fig. 36 Effects of GMG-43AC on the expression of Pref-1 during adipocyte differentiation. 3T3-L1 
cells were treated with GMG-43AC (300, 500, 1000, 2000 µM) for (A) 12 hours, (B) 48 hours, (C) 4 days 
or (D) 10 days of adipogenesis. Data are the mean ± SEM of at least four determinations for each time 
point. Significantly different from CTR Pref-1, *P<0.05, **P<0.01, ***P<0.001. 
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5.2.4. Effect of GMG-43AC on actin cytoskeleton reorganization 
in 3T3-L1 adipocytes 
We also studied the effect of  GMG-43AC on actin cytoskeleton reorganization in 
the 3T3-L1 cells by means of immunofluorescence. The actin cytoskeleton is composed 
of actin filaments and many specialized actin-binding proteins (Takai Y et al., 2001). 
For this experiment cells were differentiated in adipocytes for 3 and 6 days in the 
presence of the drug and analyzed for actin cytoskeleton organization after the staining 
with fluorescent phallotoxin. The phallotoxin was isolated from the deadly Amanita 
phalloides which binds specifically at the interface between F-actin subunits 
(see Materials and methods). 
Our results show that  that differentiating 3T3-L1 cells treated for 3 days with the doses 
300 µM and 500 µM of GMG-43AC did not have any strong differences in actin 
filament rearrangement in relation to non treated adipocytes (Fig. 37, panels B-D). 
However, the dosages 1000 µM and 2000 µM of drug made redistribution of actin 
filaments to the terminal point of the cells (Fig. 37, panels E-F). 
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Fig. 37 Immunofluorescence images of actin localization in 3T3-L1 cells differentiated in adipocytes 
for 3 days  in the presence of GMG-43AC. (A) preadipocytes;  (B) adipocytes; (C) adipocytes 3T3-L1 
cells treated with 300 µM GMG-43AC; (D) adipocytes 3T3-L1 cells treated with 500 µM GMG-43AC; 
(E) adipocytes 3T3-L1 cells treated with 1000 µM GMG-43AC; (F) adipocytes 3T3-L1 cells treated with 
2000 µM GMG-43AC. 
 
On the other hand, 3T3-L1 cells differentiated in the presence of GMG-43AC for 6 days 
show actin membrane ruffling starting from the dose of 500 µM (Fig. 38, panels B-F). 
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Fig. 38 Immunofluorescence images of actin localization in 3T3-L1 cells differentiated in adipocytes 
for 6 days in the presence of GMG-43AC. (A) preadipocytes;  (B) adipocytes; (C) adipocytes 3T3-L1 
cells treated with 300 µM GMG-43AC; (D) adipocytes 3T3-L1 cells treated with 500 µM GMG-43AC; 
(E) adipocytes 3T3-L1 cells treated with 1000 µM GMG-43AC; (F) adipocytes 3T3-L1 cells treated with 
2000 µM GMG-43AC. 
 
The effect of GMG-43AC on actin cytoskeleton reorganization in 3T3-L1 cells showed 
above was also investigated evaluating the expression of Small GTP binding protein 
RhoA by means of western blotting. Cells were differentiated in adipocytes for 7 days 
in the presence of investigated dosages of the drug and analyzed for presence of RhoA 
protein. RhoA is a master regulator of various cellular processes such as cell migration, 
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adhesion, cytokinesis, cell cycle progression, vesicular trafficking, and cytoskeletal 
regulation. RhoA works as a molecular switch, shuttling between the GDP-bound 
inactive form and the GTP-bound active form (Nakayama Y. et al,. 2009). 
Our results suggest that after 7 days of differentiation RhoA was expressed at high 
levels in 3T3-L1 cells. Its levels were drastically reduced in a dose-dependent manner 
after the treatment with GMG-43AC (Fig. 39). 
 
Fig. 39 Western blotting analysis of RhoA in 3T3-L1 cells after 7 days of differentiation. At 
the indicated time cells were lysed with RIPA buffer. Sixty micrograms of total protein extracts were 
separated in denaturing SDS-PAGE and transferred onto nitrocellulose membrane. RhoA antibody was 
used to this study. 
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5.2.5. GMG-43AC induced lipolysis of triglycerides in 3T3-L1 cells 
In this experiments the effect of GMG-43AC on lipolysis was investigated. Lipolysis 
was assessed by the amount of glycerol released into media in 3T3-L1 cells treated for 2 
(Fig. 40, green columns), 4 (Fig. 40, orange columns) or 7 (Fig. 40, blue columns) days 
with the drug (scheme 1) after the activation of HSL (see Materials and methods).  
Our data shows that the amount of glycerol released into media was significantly 
increased during the adipocyte differentiation as expected. These results suggest that the 
activity of hormone-sensitive lipase (HSL) was raised for the duration of adipogenesis 
(Fig. 40).  Moreover, as shown in this figure (green columns), exposure to GMG-43AC 
(doses 300-1000 µM) for the initial 2 days of differentiation, significantly increased the 
levels of glycerol released into the media by the 3T3-L1 cells. Contrastively, during the 
treatment with the dose 2000 µM we were not able to find any increase of glycerol 
release. Probably because of the fact that this dosage markedly abolished 
the differentiation of 3T3-L1 cells and synthesis of triglycerides. As a consequence, 
there was no substratum for activity of HSL (Fig. 40, green columns). 
Then we evaluated the levels of glycerol on 4th day of differentiation in the presence of 
the drug. Our results indicated that the amount of glycerol released into the media was 
down-regulated in dose-dependent manner (Fig. 40, orange columns). It might be an 
effect caused by insulin which was in the culture medium on the 4th day of 
differentiation. It has been reported that insulin inhibits lipolysis via phosphorylation 
and activation of phosphodiesterase 3B, which in turn lowers cAMP levels (see 
Materials and Methods) (Kershaw EE et al., 2006). We suppose that GMG-43AC 
potentiated the inhibitory effect of insulin. 
Thus, the significant increase of glycerol released into media was observed after 7 days 
treatment with 300 µM of GMG-43AC. However, dosages of 1000 and 2000 µM of 
drug markedly abolished the activity of HSL probably because of the fact that these 
dosages almost completely inhibited the differentiation process and as a consequence 
there was no substratum for activity of HSL (Fig. 40, blue columns). 
RESULTS 
91 
 
 
Fig. 40 GMG-43AC stimulates lipolysis in 3T3-L1 cells. 3T3-L1 preadipocytes were differentiated in 
presence of GMG-43AC (300-2000 µM) for 2(green), 4 (orange) and 7 (blue) days. Lipolysis was 
assessed by the amount of glycerol released into media. Data are expressed as mean ± S.E.M of 
3 experiments. Significantly different from DIFF (2d), DIFF (4d) and DIFF (7d) respectively, *P<0.05, 
**P<0.01, ***P<0.001. 
 
The effect of GMG-43AC on lipolysis was also investigated by means of real time    
RT-PCR. Our results show that exposure to GMG-43AC significantly reduced mRNA 
levels of  HSL. This inhibitory action was evident starting from the dosage 1000 µM. 
Interestingly, the dosage of 300 µM raised mRNA levels (Fig. 41). Data was 
comparable to that of lipolysis measurement (Fig. 40). 
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Fig. 41 Analysis of HSL mRNA levels by Real-Time PCR after GMG-43AC treatment. Levels of 
HSL mRNA were assessed in mature 3T3-L1 adipocytes after 10 days of treatment. Data are expressed as 
mean ± S.E.M of 3 experiments. Significantly different from DIFF HSL, *P<0.05, **P<0.01, ***<0.001. 
 
 
5.2.6. Permanent inhibitory effect of GMG-43AC on 
adipocyte differentiation in 3T3-L1 cells 
To examine whether GMG-43AC inhibitory effect on adipocyte differentiation was 
stable, the 3T3-L1 cells were differentiated in the presence of drug for 10 days 
(scheme 1) then the drug was removed and cells were maintained in the maintenance 
medium for the following 14 days without the drug. As shows in figure 42, the 
accumulation of triglycerides in two experiments was similar. Moreover, there were no 
any significant differences between 10-days treatment (Fig. 42, green columns) and 10-
days treatment with following 14-days incubation (Fig. 42, red columns) (P<0.05). 
Collectively, 3T3-L1 cells differentiated in adipocytes in the presence of GMG-43AC 
and subsequently incubated in the maintenance medium for 14 days, did not restart to 
synthesize and accumulate triglycerides. Furthermore, the results suggested that GMG-
43AC inhibition of triglycerides synthesis was permanent and achieved the significant 
effects at the maximal tested concentrations of 1000 µM and 2000 µM (P<0.001) 
(Fig. 42).  
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Fig. 42 GMG-43AC permanently inhibits adipocyte differentiation in 3T3-L1 cells. 3T3-L1 
preadipocytes were differentiated in presence of GMG-43AC (300-2000 µM) for 10 days (green 
columns) and then cells were incubated in the maintenance medium for the following 14 days without the 
drug (red columns). Levels of accumulated triglycerides (labelled with Oil Red O) were quantified as 
evidenced by absorbance at 500 nm wavelength. Each experimental condition was assayed in triplicate 
and the graph is referred to the means of three independent experiments. Data are expressed as mean 
± S.E.M of 3 experiments. Significantly different from DIFF (10d), *P<0.05, **P<0.01, ***P<0.001; 
Significantly different from DIFF (24d), $P<0.05, $$<P<0.01, $$$P<0.001. 
 
The effect of GMG-43AC on adipocyte differentiation was also investigated after 
5 weeks of drug treatment. Briefly, 3T3-L1 cells were differentiated as described before 
(see Materials and Methods) in the presence of GMG-43AC. The treatment was 
prolonged until 5 weeks to evaluate whether the doses 300 μM and 500 μM of the drug 
will become more effective in the inhibition of adipocyte differentiation. 
Our results show that the dose of 500 μM of GMG-43AC left in the culture medium for 
5 weeks became more effective in the inhibition of differentiation in respect to the 
treatment for 10 days (Fig. 43). 
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Fig. 43 Treatment with GMG-43AC of 3T3-L1 cells for 5 weeks. 3T3-L1 preadipocytes were 
differentiated in presence of GMG-43AC (300-2000 µM) for 10 days (blue columns) or 5 weeks (red 
columns). Levels of accumulated triglycerides (labelled with Oil Red O) were quantified as evidenced by 
absorbance at 500 nm wavelength. Each experimental condition was assayed in triplicate and the graph is 
referred to the means of three independent experiments. Data are expressed as mean ± S.E.M of 
3 experiments. Significantly different from DIFF (10d), *P<0.05, **P<0.01, ***P<0.001; Significantly 
different from DIFF (24d), $P<0.05, $$<P<0.01, $$$P<0.001. 
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5.3. GMG-43AC inhibition of lipids accumulation during 3T3-L1 
differentiation in adipocyte promoting medium: 
results of scheme 2 
GMG-43AC was applied during the first 2 days of differentiation process, that is 
defined as the inductive period. In this condition the only effective dose was 2000 µM 
that caused an inhibition of 60%.  The doses lower than 1000 µM had no effect (Fig. 44 
and 45). 
 
Fig. 44 Oil Red O staining of undifferentiated 3T3-L1 cells and adipocytes. Percentage of positive 
cells in reference to total cell population. Reported values (mean ± SEM) are the result of two 
independent experiments and for each experiment 5 fields were considered for each condition. 
Significantly different from DIFF (10d), *P<0.05,  **P<0.01, ***P < 0.001. 
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Fig. 45 Levels of accumulated triglycerides (labeled with Oil Red O) in 3T3-L1 undifferentiated cells and 
adipocytes as evidenced by quantitative absorbance at 500 nm wavelength. Each experimental condition 
was assayed in triplicate and the graph is referred to the means of one experiment. Values are mean 
± SEM. Significantly different from DIFF (10d), *P<0.05, **P<0.01, ***P<0.001. 
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5.4. GMG-43AC inhibition of lipids accumulation during 3T3-L1 
differentiation in adipocyte promoting medium: 
results of scheme 3 
GMG-43AC was added to the culture medium after the first 48 hours of the induction 
and maintained for the following 48 hours. We observed an inhibition both adipogenesis 
and lipid accumulation. Figure 46 shows an Oil Red O staining of lipid accumulation in 
differentiated adipocytes (Fig. 46, panel A), this was previously reduced with increasing 
dosages (Fig. 46, panel B-D). The lowest effective dose was 300 µM (Fig. 47 and 48). 
 
Fig. 46 Oil Red O staining of 3T3-L1 cells with drug regimen type 3. (A) adipocytes in no drug 
medium;  (B) adipocytes grown in medium containing 500 µM GMG-43AC ; (C) adipocytes grown in 
medium containing 1000 µM GMG-43AC; (D) adipocytes grown in medium containing 2000 µM GMG-
43AC. 
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Fig. 47 Oil Red O staining of undifferentiated 3T3-L1 cells and adipocytes. Percentage of positive 
cells in reference to total cell population. Reported values (mean ± SEM) are the result of two 
independent experiments and for each experiment 5 fields were considered for each condition. 
Significantly different from DIFF (10d), *P<0.05, **P<0.01, ***P<0.001. 
 
 
Fig. 48 Levels of accumulated triglycerides (labeled with Oil Red O) in 3T3-L1 undifferentiated cells and 
adipocytes as evidenced by quantitative absorbance at 500 nm wavelength. Each experimental condition 
was assayed in triplicate and the graph is referred to the means of three independent experiments. Values 
are mean ± SEM. Significantly different from DIFF (10d), *P<0.05, **P<0.01, ***P<0.001. 
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5.5. GMG-43AC inhibition of lipids accumulation during 3T3-L1 
differentiation in adipocyte promoting medium: 
results of scheme 4 
GMG-43AC treatment of 3T3-L1 cells through the differentiation period with 
the incubation starting immediately after the induction period (after the first 48 hours) 
inhibited adipocyte differentiation and lipid accumulation in a dose-dependent fashion 
(Fig. 49). 
 
Fig. 49 Levels of accumulated triglycerides (labeled with Oil Red O) in 3T3-L1 undifferentiated cells and 
adipocytes as evidenced by quantitative absorbance at 500 nm wavelength. Each experimental condition 
was assayed in triplicate and the graph is referred to the means of three independent experiments. Values 
are mean ± SEM. Significantly different from DIFF (10d), *P<0.05, **P<0.01, ***P<0.001. 
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5.6.  Reversion of adipogenesis process by GMG-43AC 
GMG-43AC was capable of promoting the loss of accumulated triglycerides when fully 
differentiated 3T3-L1 cells were treated with the drug for 7 days (scheme 5). The effect 
was dose-dependent and significant with dose starting from 500 µM (Fig. 50, panels B-
D; Fig. 51 and Fig. 52). 
 
Fig. 50 (A) Oil Red O staining of adipocytes (differentiated for 15 days) ;  (B) Loss of accumulated fat 
with GMG-43AC treatment (500 µM); (C) Loss of accumulated fat with GMG-43AC treatment 
(1000 µM); (D) Loss of accumulated fat with GMG-43AC treatment (2000 µM). 
 
The quantification of the effects of GMG-43AC on the decrease of fat cell number and 
total fat was shown in figures 51 and 52. The reverting effect of GMG-43AC treatment 
can be observed from concentration of 500 µM and further.  
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Fig. 51 7 days reversion with GMG-43AC. Oil Red O staining of undifferentiated 3T3-L1 cells and 
adipocytes. Percentage of positive cells in reference to total cell population. Reported values 
(mean ± SEM) are the result of two independent experiments and for each experiment 5 fields were 
considered for each condition. Significantly different from DIFF (15d), *P<0.05, **P<0.01, ***P<0.001. 
 
 
Fig. 52 7 days reversion with GMG-43AC. Levels of accumulated triglycerides (labeled with Oil 
Red O) in 3T3-L1 undifferentiated cells and adipocytes after 7 days reversion with GMG-43AC as 
evidenced by quantitative absorbance at 500 nm wavelength. Each experimental condition was assayed in 
triplicate and the graph is referred to the means of two independent experiments. Values are mean ± SEM. 
Significantly different from DIFF (15d), *P<0.05, **P<0.01, ***P<0.001. 
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The ability of GMG-43AC to revert the adipocyte phenotype has also been confirmed at 
the molecular level. By means of western blotting analyses we assayed the expression 
of PPARγ and its phosphorylated form. The results show that after treating the 
differentiated 3T3-L1 cells with GMG-43AC the expression of PPARγ and its 
phosphorylated form decreased significantly. In all experimental sets the amount of 
proteins was normalized with the expression of β-actin (Fig. 53). 
 
Fig. 53 Western blotting analysis of molecular factors involved in adipogenesis. At the end the 
incubation period cells were lysed with RIPA buffer. Sixty micrograms of total protein extracts were 
separated in denaturing SDS-PAGE and transferred to a nitrocellulose membrane. Specific antibodies 
were used to study the expression of proteins involved in the reversion of adipogenesis.  
 
To examine if the reversal effect of GMG-43AC was stable, we differentiated the 3T3-
L1 cells in adipocytes and then we treated the adipocytes with the drug according to 
scheme 5. Next, the drug was removed from the culture medium and the cells were 
incubated in the maintenance medium for the following 7 days. As figure 54 clearly 
shows, the effect of GMG43AG resulted to be reversible and the cells began again to 
produce and accumulate the drops of triglycerides. 
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Fig. 54 Comparison between 7 days reversion with GMG-43AC (scheme 5) and 7 days reversion 
with successive 7 days incubation in the maintenance medium. Measurement of accumulated 
triglycerides. Orange columns: 7 days reversion; blue columns: 7 days reversion with successive 7 days 
incubation in the maintenance medium. Each experimental condition was assayed in triplicate and the 
graph is referred to the means of two experiments. Values are mean ± SEM. Significantly different from 
DIFF (15d), *P<0.05, **P<0.01, ***P<0.001. Significantly different from DIFF (22d), $P<0.05, 
$$<P<0.01, $$$P<0.001. 
 
The effect of GMG-43AC on the reversion of the adipocyte phenotype has also been 
investigated after 14 days of treatment (as presented in scheme 6, materials and 
methods). Our results show that the drug administration to 3T3-L1 cells from day 8 of 
adipogenesis for successive 14 days reverted differentiation and lipid accumulation 
beginning from 300 µM (Fig. 54). 
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Fig. 54 14 days reversion with GMG-43AC. Levels of accumulated triglycerides (labeled with Oil 
Red O) in 3T3-L1 undifferentiated cells and adipocytes after 14 days reversion with GMG-43AC as 
evidenced by quantitative absorbance at 500 nm wavelength. Each experimental condition was assayed in 
triplicate and the graph is referred to the means of two independent experiments. Values are mean ± SEM. 
Significantly different from DIFF (15d), *P<0.05, **P<0.01, ***P<0.001. 
 
Comparison between two schemes of reversion 
The following results show that GMG-43AC administration to 3T3-L1 cells for longer 
periods (14 days) reverted differentiation and lipid accumulation with a better efficiency 
and moreover, these results were observed by using lower doses (Fig. 55). 
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Fig. 55 Comparison between two reversion of adipocyte differentiation with GMG-43AC. 
Measurement of accumulated triglycerides. Green columns: 7 days reversion; violet columns: 14 days 
reversion. Each experimental condition was assayed in triplicate and the graph is referred to the means of 
two experiments. Values are mean ± SEM. Significantly different from DIFF (15d), *P<0.05, **P<0.01, 
***P<0.001. Significantly different from DIFF (22d), $P<0.05, $$P<0.01, $$$P<0.001. 
 
During the longer reversion period (as presented in scheme 6, materials and methods) 
we also investigated an effect of GMG-43AC on apoptosis. Apoptosis was studied by 
means of TUNEL assay and the results showed that the number of TUNEL positive 
cells was similar to that of adipocytes. The number of apoptotic cells was very low and 
reached a maximum percentage of 2% (Fig. 56). 
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Fig. 56 TUNEL assay after 14 days reversion with GMG-43AC. Percentage of positive cells in 
reference to total cell population. Reported values (mean ± SEM) are the result of two independent 
experiments and for each experiment 8 fields were considered for each condition. Significantly different 
from ADIPOCYTES, *P<0.05, **P<0.01, ***P<0.001. 
 
 
5.7. GMG-43AC inhibits lipid accumulation and promotes the loss 
of accumulated triglycerides in the differentiation induced by 
troglitazone: results of schemes 7 and 8  
In these sets of experiments troglitazone (TZD; 10 µM), a potent inducer of adipocyte 
differentiation, was added to culture medium in presence of insulin (10 µg/ml), and 
the adipocyte differentiation was studied at day 10 (Han KL et al., 2006). GMG-43AC 
at a different concentration was added to the culture medium (in presence of TZD and 
insulin) at day 0 and maintained until the end of the differentiation.  Our results show 
that GMC-43AC was able to counteract synthesis and accumulation of triglycerides 
induced by TZD (Fig. 57 and 58). This inhibitory action was evident starting from the 
dosage 500 µM. 
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Fig. 57 Oil Red O staining of differentiated 3T3-L1 adipocyte-like cells. Quantification of positive 
cells in presence of troglitazone with or without GMG-43AC treatment. Reported values (mean ± SEM) 
are the result of three experiments. 8 fields were considered for each condition. Significantly different 
from DIFF TZD, *P<0.05, **P<0.01, ***P<0.001. 
 
Fig. 58 Oil Red O staining of differentiated 3T3-L1 adipose-like cells. Measurement of accumulated 
triglycerides. Each experimental condition was assayed in triplicate and the graph is referred to the means 
of three experiments. Value are mean ± SEM. Significantly different from DIFF TZD, *P<0.05, 
**P<0.01, ***P<0.001. 
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The effect of GMG-43AC on TZD-promote adipocyte-like differentiation of 3T3-L1 
cells was studied also in the reversion approach (see scheme 8, materials and methods). 
We observed previously that TZD used at two different concentrations (5 and 10 µM) 
was able to induce a 3T3-L1 cell differentiation with very similar efficiency. 
To investigate the GMG-43AC reversion capability of 3T3-L1 lipids accumulation 
the differentiation was induced with 5 µM TZD for 9 days, the investigated drug was 
added at different concentrations (see fig. 59) and maintained for 8 days. GMG-43AC 
treatment reverted the lipid accumulation in a dose-dependent fashion (Fig. 59). 
 
Fig. 59 Oil Red O staining of differentiated 3T3-L1 adipose-like cells. Measurement of accumulated 
triglycerides. Each experimental condition was assayed in triplicate and the graph is referred to the means 
of three experiments. Value are mean ± SEM. Value are mean ± SEM. Significantly different from 
DIFF TZD 5µM, *P<0.05, **P<0.01, ***P<0.001. 
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5.8. Comparison between the action of GMG-43AC, GMG-43AC 
raceme mixture, caffeine, L-Thyroxine and Eutirox® (50 µg) 
The effect of GMG-43AC, its raceme mixture, caffeine, L-Thyroxine and Eutirox® on 
adipogenesis was investigated. The drugs were added in cultured medium at day 0 and 
were maintained until day 10 (see scheme 9). 
The results show that the GMG-43AC raceme mixture was as effective as GMG-43AC 
in inhibiting 3T3-L1 differentiation toward adipocyte phenotype (Fig. 35; green bar). 
As reported earlier by other authors (Nakabayashi H. et al., 2008), caffeine failed to 
inhibit the differentiation of 3T3-L1 preadipocytes to adipocytes. The inhibition was of 
the order of 20% and independent of the dosages used (Fig. 35; violet bars). 
Eutirox® is a drug which consists of levothyroxine sodium salt (50 µg/capsule) and was 
used at 130 nM final concentration. Treatment with this drug practically did not affect 
lipid accumulation during 3T3-L1 differentiation into adipocytes (Fig. 35; yellow bars). 
 
Fig. 60 Levels of accumulated triglycerides (labeled with Oil Red O) in 3T3-L1 undifferentiated cells and 
adipocytes as evidenced by quantitative absorbance at 500 nm wavelength. Each experimental condition 
was assayed in triplicate and the graph is referred to the means of three independent experiments. Values 
are mean ± SEM. Significantly different from DIFF 10d, *P<0.05, **P<0.01, ***P<0.001. 
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5.9. Comparison of the actions of GMG-43AC and 
PD98059 in adipogenesis 
As shown above, the addition of GMG-43AC to the culture medium at day 2 of 
differentiation process for the following 48 hours (see scheme 10, materials and 
methods), inhibited adipogenesis in a dose-dependent manner (Fig. 61 and 62). 
Differently, adipogenesis was enhanced when PD98059, an inhibitor of MEK1, was 
added to the culture medium. The results strongly suggested that the pathway 
MEK/ERK is likely involved in the adipogenesis process observed in 3T3-L1 cells 
(Fig. 61 and 62). 
 
Fig. 61 Oil Red O staining of undifferentiated 3T3-L1 cells and adipocytes. Percentage of positive 
cells is refereed to total cell population. Reported values (mean ± SEM) are the result of two independent 
experiments and for each experiment 5 fields were considered for each condition. Significantly different 
from DIFF 10d, *P<0.05; **P < 0.01; ***P < 0.001. 
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Fig. 62 Levels of accumulated triglycerides (labeled with Oil Red O) in 3T3-L1 undifferentiated cells and 
adipocytes as evidenced by quantitative absorbance at 500 nm wavelength. Each experimental condition 
was assayed in triplicate and the graph is referred to the means of three independent experiments. Values 
are mean ± SEM. Significantly different from DIFF 10d,  *P<0.05, **P < 0.01, ***P < 0.001. 
 
The effect of GMG-43AC and PD98059 on adipocyte differentiation was also evaluated 
after 4 days with PD98059 and GMG-43AC added between days 2 and 4 (see 
scheme 11, materials and methods). It may be noted that the proadipogenic action of 
PD98059 was rapid almost doubling the lipid accumulation in 48 hours (Fig. 63). 
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Fig. 63 Levels of accumulated triglycerides (labeled with Oil Red O) in 3T3-L1 undifferentiated cells and 
adipocytes as evidenced by quantitative absorbance at 500 nm wavelength. Each experimental condition 
was assayed in triplicate and the graph is referred to the means of three independent experiments. Values 
are mean ± SEM. Significantly different from DIFF 4d, *P<0.05, **P < 0.01, ***P < 0.001. 
 
 
  
6. DISCUSSION 
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Obesity is one of the world's greatest public health challenges, contributing to morbidity 
and mortality through the increased risk for many chronic diseases, including type-
2 diabetes mellitus, hypertension, dyslipidemia, coronary artery disease, stroke, 
osteoarthritis and certain forms of cancer (Youngson N. A. et al., 2012). The increasing 
prevalence of overweight and obesity has been observed worldwide, and obesity is 
likely to continue to be an important risk factor for the health of all populations, in 
particular of those in developing countries (Day F. R. et al., 2011). The main reasons of 
obesity are rising incomes, increasing urban populations, diets high in fats and simple 
sugars, and societal changes (Haidar Y. M. et al., 2011). 
Obesity is defined as an excessively high amount of body fat or adipose tissue in 
relation to lean body mass. Obesity is characterized by the accumulation of adipose 
tissue, which expands due to an increase in adipocyte size (hypertrophy) and number 
(hyperplasia). Today several cellular models are available to study adipogenesis. 
The most frequently employed murine cell line is 3T3-L1. In-vitro-differentiated 3T3-
L1 adipocytes have many characteristics of adipose cells in vivo (Gregoire F. M. et al., 
1998). 
In the present study, we evaluate the effect of GMG-43AC, the new experimental drug 
of Giuliani Sp. A. (Milan, Italy), on adipogenesis induced in post-confluent 3T3-L1 
preadipocytes exposure to hormone stimulants (IBMX, DEX and insulin) or 
troglitazone, the potent activator of the peroxisome proliferator-activated receptor γ 
(PPARγ). In addition, we also investigate the ability of GMG-43AC to revert the 
adipocyte differentiation process induced by hormone mixture or troglitazone. 
We observed that GMG-43AC inhibited 3T3-L1 preadipocyte differentiation, and 
moreover it was able to revert the adipocyte phenotype into fully differentiated 
adipocytes. 
It has been demonstrated that adipose alteration in tissue mass is related to the number 
of adipocytes. Thus, one strategy to reduce adiposity would be to reduce adipocyte 
numbers and fat content of adipocytes. Mature adipocytes are round and filled with 
many lipid droplets, which is distinguished from fibroblast-like preadipocytes in 
morphology. In the current study, GMG-43AC treatment reduced lipid accumulation in 
all investigated types of treatment, as shown by decreases in the percentage of lipid 
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area. These observations were further confirmed by by the counting of Oil Red O 
positive stained cells compared to all the cells indicated by hematoxylin staining.  
Moreover, we showed that after the removal of the drug from 3T3-L1 cells 
differentiated in adipocytes in the presence of GMG-43AC, cells did not resume to 
synthesize and accumulate triglycerides. This result suggests that GMG-43AC 
inhibition of triglycerides synthesis was permanent and achieved the significant effects 
at the maximal tested concentration of 2000 µM. Interestingly, the drug left in the 
culture medium for a longer period (5 weeks) became more effective in the inhibition of 
differentiation with respect to the treatment for 10 days. Importantly, the results of 
TUNEL assay showed that the number of apoptotic cells was similar to that of non-
treated adipocytes and reached a maximum percentage of 2%. 
The differentiation of preadipocytes is regulated by a complex network of 
transcriptional factors. At the centre of this network are the nuclear receptor PPARγ and 
members of the C/EBP family (CCAAT/enhancer binding protein) which are important 
for adipogenesis. PPARγ has been shown to be sufficient and necessary for 
adipogenesis in 3T3-L1 preadipocytes and also is required for maintenance of the 
differentiated state (Gregoire F. et al., 1998; Xing Y. et al., 2010). Moreover, C/EBPα is 
essential for the terminal differentiation (Rosen E. D. et al., 2006). In the presence of 
hormonal stimulants, C/EBPβ and C/EBPδ levels increase rapidly and then 
synergistically stimulate the expression of PPARγ and C/EBPα, which cross-regulate 
each other through a positive feedback (Rosen ED et al., 2006; Xing Y et al., 2010). The 
present study indicated that GMG-43AC 10-day treatment inhibited the expression of 
PPARγ and C/EBPα both at mRNA and protein levels. Thus, GMG-43AC inhibited 
adipogenesis by suppressing the expression of the transcriptional factor required for the 
differentiation process. The downstream target genes of PPARγ and C/EBPα, such as 
FABP-4 and leptin, are adipocyte-specific genes involved in maintaining adipocyte 
phenotype. These genes are regulated by PPARγ and C/EBPα, and the inhibitory effect 
of GMG-43AC on FABP-4 and leptin may be mediated by inhibition of the two 
transcriptional factors’ expression. Furthermore, the exposure to GMG-43AC during the 
initial 48 hours of adipocyte differentiation markedly reduced C/EBPβ levels in a dose-
dependent manner with the exception of the dose of 300 µM. Interestingly, this dosage 
slowed down the degradation of C/EBPβ at 48 hours of differentiation. Our results show 
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that the experimental drug also markedly reduced protein levels of C/EBPδ at the lower 
dose of 300 μM. In contrast, further doses did not influence C/EBPδ expression after 48 
hours of treatment.  
Lipolysis plays a central role in the regulation of energy balance. The control of 
lipolysis is complex and involves multiple players such as lipolytic (β-adrenergic 
agonists, ACTH, etc.) and anti-lipolytic (insulin, adenosine, etc.) hormones, their 
cognate receptors and signalling pathways, lipid droplet-associated proteins, such as 
perilipins, and hormone-sensitive lipase (HSL), which is the rate-limiting enzyme 
responsible for mediating the hydrolysis of triglycerides (Greenberg A. S. et al, 2001). 
Our results showed that exposure to GMG-43AC significantly reduced activity and 
mRNA levels of HSL, and this inhibitory action was evident starting from the dosage of 
1000 µM. 
In summary, the data demonstrated that 10-day treatment with GMG-43AC inhibited 
3T3-L1 preadipocyte differentiation via the suppression of C/EBPβ, PPARγ and 
C/EBPα, although the effects of GMG-43AC on adipose tissue remain to be determined 
in vivo. Inhibition of adipogenesis may regulate the amount of adipose tissue and, as a 
consequence, decrease the number of obese persons. Our study could provide an 
alternative approach for the treatment of obesity.  
We also noticed that GMG-43AC was capable of promoting the loss of accumulated 
triglycerides when fully-differentiated 3T3-L1 cells were treated with the drug. 
Moreover, the reverting effect of GMG-43AC treatment can be observed from 
concentrations of 500 µM and greater. Unfortunately, this result was reversible and the 
cells were able to re-synthesize and accumulate the drops of triglycerides when they 
were left without the treatment. Interestingly, the drug left in the culture medium for the 
period of 14 days became more effective in the reversion of differentiation with respect 
to the treatment for 7 days. The accurate mechanisms that regulate loss of accumulated 
triglycerides in fully-differentiated adipocytes are still unclear. Our initial data have 
shown that exposure of the differentiated 3T3-L1 cells to GMG-43AC decreased the 
total expression of PPARγ.  
In conclusion, further study is still needed to explore clearly the molecular mechanism 
explained by the inhibitory and reversion effects of GMG-43AC involved in the fat loss 
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phenomenon. However, GMG-43AC has the potential to be an innovative product for 
the prevention and treatment of obesity. 
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cer (30) give rise to future applications of 2D pH sensors in
studying tumor metabolism.
Acknowledgements
This work was supported by grants from the German Research Foundation
DFG (grants BA3410/4–1 and WO669/9–1). Traumasept Wound Gel was sup-
plied by Dr. August Wolff GmbH & Co. KG (Bielefeld, Germany).
Author contributions
S.S., R.J.M., O.S.W. and P.B. conceived the experiments. S.S., R.J.M., K.T.W.,
J.C. and D.F. performed the experiments. S.S., R.J.M. and D.F. analysed the
data. S.S. and R.J.M. wrote the paper. S.G. helped to interpret data.
Conflict of interests
None declared.
References
1 Bickers D R, Lim H W, Margolis D et al. J Am
Acad Dermatol 2006: 55: 490–500.
2 Gurtner G C, Werner S, Barrandon Y et al.
Nature 2008: 453: 314–321.
3 Martin P. Science 1997: 276: 75–81.
4 Schreml S, Szeimies R M, Prantl L et al. Br J
Dermatol 2010: 163: 257–268.
5 Schreml S, Szeimies R M, Karrer S et al. J Eur
Acad Dermatol Venereol 2010: 24: 373–378.
6 Dickinson B C, Chang C J. Nat Chem Biol
2011: 7: 504–511.
7 Niethammer P, Grabher C, Look A T et al. Nat-
ure 2009: 459: 996–999.
8 Yoo S K, Starnes T W, Deng Q et al. Nature
2011: 480: 109–112.
9 Muller P, Schier A F. Dev Cell 2011: 21:
145–158.
10 Bumke M A, Neri D, Elia G. Proteomics 2003:
3: 675–688.
11 Olson E R. Mol Microbiol 1993: 8: 5–14.
12 Borsi L, Balza E, Gaggero B et al. J Biol Chem
1995: 270: 6243–6245.
13 Sharpe J R, Harris K L, Jubin K et al. Br J Der-
matol 2009: 161: 671–673.
14 Paradise R K, Lauffenburger D A, Van Vliet K J.
PLoS One 2011: 6: e15746.
15 Behne M J, Meyer J W, Hanson K M et al. J
Biol Chem 2002: 277: 47399–47406.
16 Hachem J P, Behne M, Aronchik I et al. J Invest
Dermatol 2005: 125: 790–797.
17 Goerges A L, Nugent M A. J Biol Chem 2003:
278: 19518–19525.
18 Hinman C D, Maibach H. Nature 1963: 200:
377–378.
19 Winter G D. Nature 1962: 193: 293–294.
20 Winter G D, Scales J T. Nature 1963: 197:
91–92.
21 Walpole G S. Biochem J 1914: 8: 131–133.
22 Meier R J, Schreml S, Wang X D et al. Angew
Chem Int Ed Engl 2011: 50: 10893–10896.
23 Schreml S, Meier R J, Wolfbeis O S et al. Proc
Natl Acad Sci U S A 2011: 108: 2432–2437.
24 Schreml S, Meier R J, Wolfbeis O S et al. Exp
Dermatol 2011: 20: 550–554.
25 Fischer L H, Borisov S M, Schaeferling M et al.
Analyst 2010: 135: 1224–1229.
26 Borisov S M, Krause C, Arain S et al. Adv
Mater 2006: 18: 1511–1516.
27 Liebsch G, Klimant I, Krause C et al. Anal
Chem 2001: 73: 4354–4363.
28 Schaferling M. Angew Chem Int Ed Engl 2012:
51: 3532–3554.
29 Neri D, Supuran C T. Nat Rev Drug Discov
2011: 10: 767–777.
30 Arwert E N, Hoste E, Watt F M. Nat Rev Can-
cer 2012: 12: 170–180.
Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Figure S1. Region of interest in a split skin donor
site wound.
Figure S2. Demonstration of complete sensor
removal.
Figure S3. Visualization of pH heterogeneity in
wounds.
Figure S4. Visualization of bacteria-induced pH
changes.
DOI: 10.1111/exd.12029
www.blackwellpublishing.com/EXD
Letter to the Editor
A specific combination of zeaxanthin, spermidine and rutin
prevents apoptosis in human dermal papilla cells
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Abstract: Hair follicle (HF) regression is characterized by the
activation of apoptosis in HF cells. Dermal papilla cells play a
leading role in the regulation of HF development and cycling.
Human follicular dermal papilla cells (HFDPC) were used to
investigate the protective activities of rutin, sperimidine and
zeaxanthine. HFDP cell incubation with staurosporine caused
apoptosis, which was completely inhibited by exposure to rutin
(2.2 lM), spermidine (1 lM) and zeaxanthin (80 lM). These
agents were much less effective when applied as single
compounds. Moreover, treatment preserved the expression of
anti-apoptotic molecules such as Bcl-2, MAP-kinases and their
phosphorylated forms. In conclusion, the investigated agents may
represent an effective treatment for the prevention of apoptosis,
one of the leading events involved in hair bulb regression.
Key words: dermal papilla cells, hair follicle, rutin, spermidine,
zeaxanthin
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Background
The hair follicle (HF) is a skin appendage with complex structure
and functions. It is formed by an invagination of the dermis down
to the hypodermis and is located in the subcutaneous tissue (1–4).
Dermal papilla cells (DPCs), located in the bulbar zone of the HF,
play a leading role in the regulation of HF development and
cycling regeneration (5–7). DPCs are specialized cells with the
ability to induce new HF formation (8,9). HF undergoes cycles in
which stages of rapid growth and hair shaft formation (anagen)
alternate with apoptosis-driven regression (catagen) and relative
HF quiescence (telogen) (10). This cycle is regulated by factors
that promote proliferation, differentiation and survival, while
regression is characterized by the activation of apoptotic pathways
in distinct cell populations (11–14).
Question addressed
The effects of three active compounds (sperimidine, rutin and
zeaxanthin) were investigated in the counteraction of apoptosis in
human dermal papilla cells (HFDPC).
Experimental design
The action of sperimidine, rutin and zeaxanthin was investigated
in human follicular dermal papilla cells (HFDPC) maintained in
vitro. Apoptosis was induced 24 h after incubation with 1 lM
staurosporine added to the culture medium (15). Apoptosis was
monitored by assaying caspase-3 activity and DNA fragmentation
using a TUNEL assay and by examining the expression of
pro- and anti-apoptotic proteins via Western blotting.
Results
Following a 24-h exposure to staurosporine (1 lM; 15), HFDPC
showed marked activation of caspase-3, cytoskeletal degradation,
nuclear blebbing and cellular fragmentation (Figs. S1A–C).
Compounds were added at specific concentrations (details in
Table SI; Fig. 1) to the growth medium together with 1 lM
staurosporine, and 24 h later, caspase-3 activity was determined
(see Data S1). Compounds were added alone (Fig. 1a), or in dif-
ferent combinations (Figs. 1–b–c). The most effective single agent
was rutin, as at a concentration of 22 lM, it reduced caspase-3
activity by 50%. Sperimidine (1 lM) alone decreased caspase-3
activity by 40%, and zeaxanthin (8 lM) reduced activity by
approximately 30%. Higher zeaxanthin concentrations had no
protective activity; however, 8 lM of zeaxanthin co-administered
with rutin (22 lM) enhanced the effect of rutin (Fig. 1b). The
addition of spermidine or zeaxanthin to rutin enhanced the anti-
apoptotic action of only 2.2 lM rutin (Fig. 1b). Almost all triple
combinations resulted in an improved activity compared with the
addition of a double combination (Fig. 1c). The most effective
agent was rutin (2.2 lM), zeaxanthin (80 lM) and spermidine
(1 lM). HFDPC exposed to staurosporine were subjected to apop-
tosis. However, when incubated with the active compounds (1 lM
spermidine; 2.2 lM rutin; 80 lM zeaxanthin) and staurosporine,
HFDPC maintained their normal shape and apoptosis was coun-
teracted. Caspase-3 is normally present around the nucleus, but it
increased in a diffuse manner throughout the cell after stauro-
sporine exposure; drug treatment only mildly affected this
increase. In HFDPC, treatment abolished the activation of cas-
pase-3 (Fig. 1c) and DNA fragmentation, and the extent of cell
death was reduced to almost control levels (Fig. S2A). The anti-
apoptotic action of the compound mixture was also assessed in
Outer Root Sheath (ORS) and mesenchymal stem cells by a TUN-
EL assay. We observed comparable results to those reported above
for HFDPC (Fig. S2B). The expression of caspase-3 and PARP in
HFDPC was enhanced by staurosporine and inhibited by
treatment with spermidine, rutin and zeaxanthin (Fig. S3A).
The execution of caspase-mediated apoptosis relies on the interac-
tion between pro-apoptotic and anti-apoptotic members of the
Bcl-2 family (16). The importance of the balance between Bcl-2
and Bax in the sensitivity of different hair bulb cell types to resist-
ing DNA damage-induced apoptosis by ionizing irradiation was
recently reported by Sotiropoulou et al. (14). In our study, we
found that incubation with staurosporine modified the expression
of Bcl-2 in HFDPC, thus creating a disequilibrium that was inhib-
ited with treatment (Fig. S3B). The efficacy of drug treatment in
counteracting apoptosis was further supported by the full preser-
vation of Akt and ERK activities in those experimental conditions
(Fig. S3C).
Figure 1. Reduction in caspase-3 activity and prevention of staurosporine
apoptotic action in HFDP cells by active compounds. The actions of spermidine
(SP), rutin (RU) and zeaxanthin (ZEA) were investigated following their addition to
growth medium together with staurosporine (ST; 1 lM). (a) The effect of the
compounds added as single agents; (b) and (c) the effect of different
combinations. Caspase-3 activity is reported as O.D. measured at 405 nm as a
percentage of the effects of ST treatment. The dashed line represents basal
caspase-3 activity in untreated cells. Each experimental condition was assayed in
triplicate, and reported data are the mean of three independent experiments.
Values are mean ± SEM. *Significantly different from control, *P < 0.05;
**P < 0.01; ***P < 0.001.
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Conclusions
Hair follicles undergo cycles of organ transformation, in which
stages of rapid growth and hair shaft formation (anagen)
alternate with stages of apoptosis-driven HF regression (cat-
agen) and relative HF quiescence (telogen) (10). The media-
tors responsible for regulating the cyclic action of the follicles
include dozens of factors that have been studied in several cell
signalling pathways, like those involved with the initiation of
apoptosis (1,17). HFDPC play a major regulatory role in the
complex cell biology of the hair follicle (18,19). During adult
hair follicle cycling, the signalling between epithelial keratino-
cytes and underlying specialized mesenchymal dermal papilla
cells induces stem cell proliferation and initiates the cascade of
cell differentiation into the HF cell lineages. Moreover, HF
regression is driven by apoptotic events that also involve DP
cells during early catagen (20). For these reasons, HFDPC
represent a reliable in vitro model system to investigate the
action of potential therapeutic agents (21). In this study, we
originally observed that apoptosis in DP cells was prevented
by co-incubation with rutin, spermidine and zeaxanthin.
The anti-apoptotic action of the compounds is likely due to
suppression of caspase-3 expression, preservation of phosphor-
ylated Akt and ERK, and counteraction of Bcl-2 loss. Previ-
ously, it was shown that flavonoids with a chemical structure
similar to rutin exerted anti-apoptotic actions by blocking the
activity of caspase-3 (22–25), zeaxanthin could reduce the
extent of nuclear fragmentation and typical apoptotic events in
photoreceptors (26), and polyamines may be involved in pro-
motion of hair growth (27–29). Taken together, these data
may explain the greater protective effects that our compounds
exhibited in combination rather than as single agents. In con-
clusion, the combination of rutin, spermidine and zeaxanthin
enhanced the survival of dermal papilla cells via the counter-
action of apoptosis, one of the leading events involved in hair
bulb regression.
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